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Alternative splicing is a fundamental mechanism that allows the generation of 
multiple isoforms of the same pre-mRNA. Although splicing is a necessary process in all 
eukaryotes from yeast to mammals, alternative splicing is more prevalent in higher than 
lower eukaryotes, and especially in vertebrates. Nearly 95% of mammalian genes undergo 
alternative splicing, so mis-regulation of this process may contribute to the development of 
different diseases such as cancer. This higher level of regulation requires additional proteins 
to facilitate the correct positioning of the spliceosomal subunits on the primary transcript. 
Here, we reveal a role for DIDO3, one of the three Dido gene products, in SFPQ binding and 
alternative splicing. Previous studies in our laboratory established binding to H3K4Me3 
through a PHD domain located at the amino terminal region of the protein. A TFS2M domain 
at the central part of DIDO3 promotes association with the RNAPII jaw during transcription 
elongation. Now, we show interaction between the carboxy-terminus of DIDO3 and SFPQ, a 
known splicing factor. SFPQ is a protein that associates with the polypyrimidine tract, and in 
particular facilitates correct U2 snRNP positioning on the 3’ splice site of exons. The 
generation of a Dido mutant lacking DIDO3 while preserving the other two isoforms 
suppressed binding of SFPQ to RNA and increased skipping for a large general group of 
exons. Exons containing SRSF1 recognition sequences however were included more 
efficiently. Alternative splicing was also studied in the context of another Dido mutant. The 
deletion of the amino terminal region of DIDO3, too, resulted in alternatively spliced exons, 
although the observed splicing defects were milder. In this mutant, downstream T-rich 
regions, associated with RNA polymerase II pause sites, facilitated the inclusion of their 
upstream exons.  
Together, our results indicate that the DIDO3-SFPQ association regulates alternative 
splicing. Due to its modular structure, DIDO3 could act as a bridge between RNA polymerase 
II and SFPQ, and thereby control the recruitment of the latter to the nascent RNA. Lack of 
the DIDO3-specific domain reduces SFPQ availability for the RNA and promotes the skipping 
of exons that are highly SFPQ-dependent. Although alternative pathways also regulate exon 
inclusion or skipping, we propose that the DIDO3-SFPQ axis in particular has evolved to 
expand alternative splicing regulation and maintain RNA splicing efficiency in mammals. 
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 El splicing alternativo es un mecanismo fundamental que permite la generación de 
múltiples isoformas de proteínas a partir del mismo ARN mensajero. Aunque este es un 
proceso necesario en todos los organismos eucariotas desde levaduras hasta mamíferos, el 
splicing alternativo es más común en eucariotas superiores como los vertebrados. Casi el 95% 
de los genes de mamíferos hacen splicing alternativo, por lo que fallos en la regulación de 
este proceso promueven la aparición de muchas enfermedades como cáncer. Este alto nivel 
de regulación requiere por tanto el uso de proteínas adicionales para facilitar el correcto 
posicionamiento de las subunidades del spliceosoma al transcrito primario. En este proyecto 
desvelamos el papel de DIDO3, uno de los tres productos del gen Dido, en la unión con SFPQ 
y el splicing alternativo. Estudios previos establecieron que DIDO3 se une a la H3K4Me3 a 
través de un dominio PHD localizado en el extremo amino terminal de la proteína, y a la 
RNAPII durante la elongación de la transcripción a través de un dominio central TFS2M. En 
esta tesis mostramos la interacción entre el extremo carboxi-terminal de DIDO3 y un factor 
de splicing conocido como SFPQ. Esta proteína se asocia al “polypyrimidine tract” y en 
concreto, facilita el correcto posicionamiento del U2 snRNP en los sitios 3’ de aceptación de 
algunos exones. La generación de un mutante de Dido carente de la isoforma DIDO3, pero 
manteniendo las otras dos isoformas, suprime la unión de SFPQ con el ARN y aumenta el 
skipping de un gran grupo de exones. Sin embargo, los exones que contienen secuencias de 
reconocimiento de SRSF1 se incluyen de una forma más eficiente. Estudiamos además el 
splicing alternativo en el contexto de otro mutante de Dido, uno carente del extremo amino-
terminal de la proteína. Aunque con esta deleción también se observaron defectos en el 
splicing alternativo, éstos eran más moderados que los del mutante del carboxi-término. En 
este mutante, regiones ricas en Timina localizadas downstream de los exones y asociadas a 
pausas de la ARN polimerasa II, facilitaban la inclusión de sus exones upstream. 
 Todos estos resultados indican que la asociación DIDO3-SFPQ regula el splicing 
alternativo. Gracias a su estructura modular, DIDO3 podría actuar como un puente entre la 
ARN polimerasa II y SFPQ, y de este modo controlar el reclutamiento de este último al ARN 
naciente. La carencia del dominio específico de DIDO3 reduce la disponibilidad de SFPQ para 
unirse al ARN y promueve el skipping de los exones dependientes de SFPQ. Aunque hay otras 
vías que regulan el splicing alternativo, proponemos que el eje DIDO3-SFPQ en particular ha 
evolucionado para aumentar el nivel de regulación del proceso y mantener la eficiencia en el 
splicing del ARN en mamíferos.
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1. The splicing process 
 RNA metabolism is a highly regulated process acting as a linker between the coding 
information (DNA) and the final executors (proteins). This process encompasses the 
synthesis, processing, export and degradation of the RNA molecules. While the synthesis is 
based on the transcription of DNA into RNA, the processing comprises the post-
transcriptional modifications of this newly synthesized RNA molecule. The mechanism 
includes capping, splicing and polyadenylation steps, to get in the end a mature messenger 
RNA. Although, in the past, transcription and processing were believed to be independent, 
we know now that this concept is not entirely correct. Both processes are frequently coupled 
and occur simultaneously (Beyer and Osheim 1988, Neugebauer 2002). 
One of the mechanisms implicated in RNA maturation is known as RNA splicing, and 
is a necessary step for the expression of most genes in eukaryotes (Iannone and Valcarcel 
2013, Kornblihtt, Schor et al. 2013). Pre-messenger RNA splicing is based on the removal of 
intronic sequences from the primary transcripts. The remaining exons are joined together to 
produce mature messenger RNAs (mRNAs) ready to be translated into proteins. Alternative 
splicing is a very flexible process that allows higher vertebrates to evolve by promoting 
proteome expansion and gene expression regulation (De Conti, Baralle et al. 2013).  
 The splicing process is highly conserved among organisms. If we visualize an RNA 
molecule as a group of randomly arranged nucleotides, then evolution had to designate 
specific sequences to show the splicing machinery where a section begins and ends. When 
this section is an intron, we refer to this mechanism as “intron definition model”. On the 
other hand, when an exon needs to be recognized, we talk about “exon definition model”. 
These two models of splicing correlate with the length of each section. While higher 
eukaryotes such as vertebrates are characterized by long introns and short exons, lower 
eukaryotes, for example yeasts, contain large exons separated by small introns. These 
differences make yeast more likely to use the intron definition model, whereas vertebrates 
would probably adapt its recognition mechanism to short exons and hence make use of an 
exon definition model (Amit, Donyo et al. 2012, De Conti, Baralle et al. 2013). 
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1.1. Spliceosome and RNA recognition sequences 
The machinery responsible for exon/intron recognition is the spliceosome, a multi-
megadalton complex formed by five uridine-rich small nuclear ribonucleoproteins (U1, U2, 
U4, U5 and U6 snRNPs). Each snRNP consists of multiple proteins and an RNA scaffold. 
These proteins assemble in a 1:1 stoichiometry to form the functional spliceosome (Wahl, 
Will et al. 2009, Will and Luhrmann 2011). In addition to the snRNPs that form the core 
spliceosome, around 150 non-snRNP proteins may help the process (Cvitkovic and Jurica 
2013). A typical human gene contains around 8 introns that need to be processed to produce 
a mature messenger RNA molecule. While only one RNA polymerase II (RNAPII) is needed to 
transcribe an entire gene, multiple spliceosomes are required to remove the introns. 
Spliceosome assembly is based on the proper recognition of specific sequences at the 
exon/intron boundaries, known as 5’ and 3’ splice sites (SS). These sites, together with the 
branch site and the polypyrimidine tract (PPT) located near the 3’SS, contain consensus 
sequences that are recognised by the snRNPs and auxiliary factors such as U2AF35 and 
U2AF65 (Figure 1) (De Conti, Baralle et al. 2013, Herzel, Ottoz et al. 2017). Despite what we 
might think, these regions are poorly conserved in metazoans (Wahl, Will et al. 2009). 
 
Figure 1. Early steps of splicing factor recruitment to pre-mRNA molecules. Small nuclear 
ribonucleoproteins (snRNPs) such as U1 snRNP and auxiliary factors (SF1, U2AF35 and U2AF65) bind to 
consensus sequences at the intron and exon boundaries. Adapted from (Kornblihtt, Schor et al. 2013). 
 During decades, two different models of spliceosome assembly were studied: (1) the 
step-wise assembly model, where individual snRNPs are assembled sequentially on a pre-
mRNA, and (2) the penta-snRNP or supra-spliceosome model, which proposes that a 
preformed spliceosome complex containing all the snRNPs binds the pre-mRNA (Rino and 
Carmo-Fonseca 2009). Past studies have defended the penta-snRNP model, as they found 
the five snRNPs to be associated in the absence of pre-mRNA (Konarska 1988, Hausner 1990, 
Wassarman 1992). However, “step-wise assembly” is the most accepted model nowadays 
(Behzadnia, Hartmuth et al. 2006). Different publications have shown that the U1 and U2 
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snRNP can bind to pre-mRNA before associating with the tri-snRNP, or even in the absence 
of a U5 snRNP (Gornemann, Kotovic et al. 2005, Lacadie and Rosbash 2005). 
According to the “step-wise assembly” model, U1 snRNP first recognises the 
canonical sequence of the 5’SS while the U2AF heterodimer (U2AF35 and U2AF35) binds to 
the PPT and 3’SS (Figure 2). The U1 interaction is stabilized by SF1 binding at the branch site. 
These proteins together with pre-mRNA form the E complex. When the U2 snRNP stably 
binds to the branch site, SF1 is displaced and U2AF auxiliary factors are removed from the 
3’SS, converting the E complex into the A complex. This step facilitates association of the 
preassembled U4/U6-U5 tri-snRNP to form the B complex. This complex undergoes several 
conformational and compositional rearrangements that provoke dissociation of the U1 and 
U4 snRNP. When the B complex is catalytically activated, two transesterification steps 
generate the RNA lariat and fuse the exons. The first catalytic step is based on a nucleophilic 
attack on the branch site adenosine by the 5’SS, promoting the transition from B to C 
complex. Further rearrangements stimulate the second transesterification reaction in which 
the 3’SS is cleaved, RNA lariat is removed, and exons are joined (Rino and Carmo-Fonseca 
2009, Wahl, Will et al. 2009). 
 
1.2. Alternative Splicing 
 The possibility to generate multiple protein isoforms by the same pre-mRNA 
sequence is based on one fundamental mechanism known as Alternative Splicing (AS). It was 
discovered together with splicing itself (Chow LT, RE et al. 1977), but only AS allows 
metazoans to extend proteome diversity without significantly increasing the number of 
genes. Different deep sequencing analyses estimate that nearly 95% of mammalian genes 
undergo alternative splicing (Wang, Sandberg et al. 2008, Barash, Calarco et al. 2010). Thus, 
mis-regulation of this process may lead to aberrant protein production and could contribute 
to multiple diseases such as cancer (Auboeuf, Carmo-Fonseca et al. 2012, Liu and Cheng 
2013, Zhang and Manley 2013, Oltean and Bates 2014, Singh and Eyras 2017), neuronal 
pathologies (Wan and Dreyfuss 2017), or muscular disorders (Singh and Eyras 2017, Wan and 
Dreyfuss 2017). Indeed, a quick search for alternative splicing and cancer in Pubmed yields 
more than seven thousand publications, highlighting the close relation of this process with 
cell development and survival. 
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Figure 2. Step-wise model of spliceosome assembly. Core spliceosome proteins bind to intronic sequences in 
a very dynamic process. All of them are recycled when the corresponding step is completed. Adapted from 
(Wahl, Will et al. 2009). 	
Alternative splicing is more prevalent in higher than in lower eukaryotes. As 
compared to the invertebrates, the vertebrates show an increased amount of genes that 
undergo AS (Keren, Lev-Maor et al. 2010). Interestingly, although yeast is an animal model 
for studying the splicing process, AS events are very rare in this organism (Howe 2003). 
However, AS may vary considerably between different vertebrates. Considering the high 
conservation of DNA sequences in vertebrates, splicing in mouse and human only share a 
low degree of similarity (Barbosa-Morais., Irimia. et al. 2012). There are different types of AS 
events (Figure 3). Whereas intron retention is the most common event found in lower 
metazoans (plants and even in fungi and protozoans), exon skipping occurrence increases 
along the phylogenetic tree together with organism complexity (Kim, Goren et al. 2008). As 
mentioned in the previous section, exon and intron length is a major determinant in the 
splicing mechanism. These differences are also important for defining AS event types. For 
example, the length of the upstream intron has a higher influence on exon selection than the 
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downstream intron (Fox-Walsh, Dou et al. 2005). In addition, in the human genome, exons 
flanked by long introns are more likely to undergo exon skipping (Fox-Walsh, Dou et al. 
2005). Although all of these factors can influence AS patterns, a huge variety of proteins 
known as splicing factors are the real regulators of this process. 
 
Figure 3. Types of alternative splicing events. Dark blue boxes represent constitutive exons. Cyan and red 
boxes depict alternative exons or introns. Black lines show constitutive splicing events while cyan lines illustrate 
alternative splicing events. 
 
1.2.1. non-snRNP splicing factors 
The non-snRNP splicing factors are proteins associated with the splicing process that 
regulate the recognition of splice sites by the spliceosome machinery. These proteins, too, 
favour the recognition of alternative splice sites and promote the removal of canonical exons 
or the inclusion of unusual ones. Thus, non-snRNP splicing factors are important to define 
alternative splicing events such as exon skipping o inclusion, even though they do not 
participate in the splicing reactions. 
Nowadays, one of the most widely accepted hypothesis about how splicing factors 
regulate alternative splicing is based on cis-regulatory sequences and trans-acting factors. It 
has been described that splicing is controlled by these regulatory sequences in the pre-
mRNA, comprised by exonic splicing enhancers (ESE), exonic splicing silencers (ESS), 
intronic splicing enhancers (ISE) and intronic splicing silencers (ISS) (House and Lynch 2008, 
Kornblihtt, Schor et al. 2013). These sequences are recognised by trans-acting factors such 
as the Serine-Arginine Splicing Factor (SRSF) family, heterogeneous nuclear 
ribonucleoproteins (hnRNPs) (Busch and Hertel 2012), as well as tissue-specific factors like 
PTB (Romanelli, Diani et al. 2013), NOVA (Jelen, Ule et al. 2007) and FOX (Lee, Tang et al. 
2009). These factors bind to spliceosomal components and may have either activating or 
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inhibitory effects on the use and recognition of the 3’ and 5’ SS (Kornblihtt, Schor et al. 2013). 
U1 snRNP recognition of the 5’SS does not require additional helper proteins because it 
interacts directly with the RNA (Spiluttini, Gu et al. 2010). However, U2 snRNP placement on 
the 3’SS seems to be guided by accessory splicing factors, among others the U2AF 
heterodimer, SRSF family or SFPQ proteins (Ruskin, Zamore et al. 1988, Patton, Porro et al. 
1993, House and Lynch 2008).  
Nonetheless, hundreds of splicing factors are implicated in AS regulation in different 
ways. SFPQ, also known as PSF (polypyrimidine tract-binding protein-associated splicing 
factor), belongs to a fascinating group of factors which regulate both splicing and 
transcription and additionally interact with components of their machineries. Aside from 
SFPQ, p54nrb/NONO, Prp40, FBP11 and TCERG1 have also been included in this category 
(Montes, Becerra et al. 2012). Both SFPQ and p54nrb/NONO are ubiquitously expressed in 
mammalian tissues. These proteins are involved in gene and transcriptional regulation, RNA 
processing, DNA repair and even snRNA nuclear export (Knott, Bond et al. 2016). Both 
interact with the spliceosome (Peng, Dye et al. 2002, Peng, Hawkins et al. 2014) and also 
with specific pre-mRNA sequences (Buxade, Morrice et al. 2008). Besides, the interaction 
between SFPQ and the hypo and hyperphosphorylated RNAPII carboxyterminal domain 
(CTD) has been published (Emili, Shales et al. 2002). However, more recent studies have 
found no connexion of SFPQ with the polymerase (Das, Yu et al. 2007).  
The SpliceAid-F database, which allows searching for published splicing factors, was 
released in 2013. This website contains a long list that covers most splicing factors found in 
humans, including their RNA binding sites, their different mutations, and related diseases 
(Giulietti, Piva et al. 2013). To directly recognize RNA molecules, most of these proteins 
contain well-known RNA binding domains (RBDs), such as RNA recognition motifs (RRM), 
KH-homology domain (KH), double-stranded RBD (dsRBD), zinc fingers (Znf) and DEAD box 
helicase domains (Lunde, Moore et al. 2007). Furthermore, recent studies have also found 
novel RBDs in flexible and disordered regions of RNA binding proteins (RBPs). These 
domains include arginine (R) and serine (S) (RS) repeats, arginine and glycine (G) (RG[G]-rich) 
repeats and lysine (K) or arginine rich sequences (K/R basic patches), which may be involved 
in both specific and non-specific interactions with messenger RNA. The same domains affect 
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RNA granule formation and participate in co- and post-transcriptional RNA metabolism 
(Castello, Fischer et al. 2016, Jarvelin, Noerenberg et al. 2016).  
 
1.2.2. RNA Polymerase II CTD 
Although splicing factors are major regulators of alternative splicing, these proteins 
not only are recruited by the nascent RNA itself but also via other proteins. The most 
extensively studied example of this protein-protein recruitment is the RNA polymerase II 
appendage known as CTD. This carboxy-terminal domain (CTD) is situated on the RNAPII 
large subunit and comprises a repetition of the heptapeptide sequence (Tyr1-Ser2-Pro3-
Thr4-Ser5-Pro6-Ser7). The number of repeats is highly conserved in every species (52 repeats 
in humans and 26 repeats in yeast) (Corden 1990). Already many years ago, the RNAPII CTD 
was implicated in coupling mRNA processing to transcription (McCracken, Fong et al. 1997) 
and its phosphorylation status was shown to have a strong effect on mRNA splicing (Hirose, 
Tacke et al. 1999). Nowadays, the way in which the post-translational modification of the 
CTD (Ser2-P, Ser5-P, Ser7-P or Thr4-P and Tyr1-P) could affect transcription and RNA 
processing has been widely studied (Nojima, Gomes et al. 2016). In budding yeast, for 
example, Ser5 and Ser7 phosphorylation occur early in transcription, during initiation and 
elongation over the first intron. On the other hand, Ser2, Thr4 and Tyr1 are phosphorylated 
during transcription of the remaining exons and termination (Herzel, Ottoz et al. 2017).  
 The impact of splicing inhibition on Ser2 phosphorylation has been studied in a 
recent publication (Koga, Hayashi et al. 2015). Here, a bidirectional regulation between 
splicing and RNAPII CTD phosphorylation patterns was proposed. Nevertheless, the 
contribution of the RNAPII CTD and splicing factors to AS outcome is still controversial. 
Several models with regard to AS regulation have been proposed over the years, among 
which the kinetic coupling model and the recruitment coupling model are the most 
widespread. 
 
1.2.3. Models associated with alternative splicing 
That splicing is mainly co-transcriptional is a widely accepted statement nowadays. 
Nevertheless, clear evidence for post-transcriptional splicing has also been published 
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(Tardiff, Lacadie et al. 2006). Various experiments identified unspliced but polyadenylated 
transcripts in the cell nucleus, suggesting that splicing can be done at different time points, 
maybe to regulate the expression of certain genes (Bhatt, Pandya-Jones et al. 2012, Boutz, 
Bhutkar et al. 2015).  
Still, many models regarding the AS process have been elaborated and most of them 
assume that splicing is carried out co-transcriptionally. Although this concept first appeared 
at the end of twentieth century, many current publications still try to decipher the precise 
moment when splicing begins. Karla Neugebauer’s group recently published a study in yeast, 
in which they measured that moment. The splicing onset occurs when RNAPII is only ±26 
nucleotides (nt) downstream the 3’SS. At this moment, 15 nt of nascent RNA are protected 
by RNAPII and 9 nt are bound by the spliceosome (Oesterreich, Herzel et al. 2016). Thus, 
intron removal starts as soon as the 3’SS emerges from RNAPII and its recognition by 
spliceosome proteins is possible. Following these findings and the co-transcriptional splicing 
concept, two main regulation models have been proposed, the recruitment and the kinetic 
coupling model.  
 
1.2.3.1. The recruitment coupling model 
The recruitment or spatial coupling model is based on the recruitment of processing 
factors to the site of transcription. This function is mostly carried out by the RNAPII CTD 
(Figure 4). The CTD has a key role in functionally linking these processes by acting as a 
“landing pad” for RNA processing factors. Not only splicing factors but also capping and 3’ 
end processing factors bind to the CTD during transcription (Custodio and Carmo-Fonseca 
2016). Indeed, the capping enzyme and the cleavage/polyadenylation (CPA) complex 
directly interact with Ser5-P (Schroeder, Schwer et al. 2000, Schwer and Shuman 2011) and 
Ser2-P (Licatalosi, Geiger et al. 2002, Ahn, Kim et al. 2004) CTD isoforms, respectively.  
Although several studies claim that splicing factors associate with the RNAPII CTD, 
whether these interactions are direct or RNA-mediated remains to be confirmed (Kornblihtt, 
Schor et al. 2013, Saldi, Cortazar et al. 2016). Besides, it was published that CTD is not 
sufficient to promote co-transcriptional splicing or capping in vivo, indicating that other 
RNAPII specific subunits or associated factors are necessary (Natalizio, Robson-Dixon et al. 
2009). One example is the mediator complex, which usually binds to enhancers and 
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promoters on the DNA. This protein complex can recruit splicing factors such as hnRNP L, 
SF3B or Eval1 (Huang, Li et al. 2012). Based on this kind of observations, a new field of study 
that considers the chromatin template itself as another source of splicing factor recruitment 
is getting stronger in the last few years. For example, histone chaperones and chromatin 
remodelers such as SWI/SNF can interfere in AS, by being incorporated into hnRNP particles 
on nascent transcripts (Tyagi, Ryme et al. 2009). Finally, even covalently modified histones 
may somehow control splicing changes. It has been published that H3K36 methylation can 
recruit polypyrimidine tract-binding protein (PTBP) and SRSF1 to the chromatin template 
with the help of other histone binders such as MRG15 and Psip1 (Luco, Pan et al. 2010, 
Pradeepa, Sutherland et al. 2012). Another example of an adaptor molecule is CHD1, which 
not only interacts with histone 3 trimethylated on lysine 4 (H3K4Me3) through its 
chromodomain but also binds the U2 snRNP subunit SF3A. When CHD1 or H3K4Me3 levels 
decrease, the association between U2 snRNP and the pre-mRNA is impaired and AS patterns 
are affected (Sims, Millhouse et al. 2007). 
 
Figure 4. Schematic representation of recruitment coupling model. Not only splicing factors but also capping 
enzymes or CPA factors are recruited through the RNAPII CTD during the transcription process. 
 
1.2.3.2. The kinetic coupling model 
 The second most studied model is kinetic coupling, which is based mainly on how 
RNAPII elongation rate and splice site strength influence AS outcome. When RNAPII 
transcribes a gene, introns and exons and therefore their splice sites and regulatory 
sequences, are exposed at different time points. On the other hand, splice sites can be weak 
or strong, based on how far their sequences diverge from the consensus sequence. Thus, 
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small variations in these two major factors could make the difference between an exon 
inclusion and an exon skipping event. 
A strong splice site is easier to recognize by the spliceosome than a weak splice site. 
In a typical transcript, weak sites are located further upstream than strong sites. Thereby, 
when the elongation rate of RNAPII is fast, both sites are exposed at nearly the same time. 
The equal exposition will favour the recruitment of splicing proteins to the strong site instead 
of the weak site, resulting in exon skipping (Figure 5, left). However, sequences that induce 
RNAPII pausing (Roberts, Gooding et al. 1998, Carrillo Oesterreich, Preibisch et al. 2010, 
Henriques, Gilchrist et al. 2013) or drugs such as Camptothecin that reduces elongation rate 
(Boireau, Maiuri et al. 2007, Ip, Schmidt et al. 2011) can facilitate the inclusion of exons with 
weak splice sites (Figure 5, right). At the same time, transcription factors that promote 
elongation (Nogues, Kadener et al. 2002) or drugs that induce an open chromatin state 
contribute to exon skipping (Batsche, Yaniv et al. 2006, Schor, Rascovan et al. 2009). This 
mechanism is also known as the “window of opportunity” model or the “first come, first 
served” model (Aebi and Weissmann 1987), because it describes a competitive system.  
 
Figure 5. Effects of the kinetic coupling model on alternative splicing. When two 3’ splice sites have different 
strength, RNAPII elongation rate is a major influencer of exon skipping or inclusion. Adapted from (Kornblihtt, 
Schor et al. 2013). 
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Nevertheless, the kinetic coupling model is not as simple as it seems. In some 
contexts, a slow RNAPII rate may favour the binding of negative regulatory splicing factors, 
which impair spliceosomal protein recruitment and promote the skipping of canonical exons 
(Dutertre, Sanchez et al. 2010, Dujardin, Lafaille et al. 2014). Another factor implicated in co-
transcriptional splicing is nucleosome occupancy. Because of the differential nucleotide 
content found in exons and introns, nucleosomes are more densely packed on exonic than 
intronic regions (Schwartz, Meshorer et al. 2009, Spies, Nielsen et al. 2009). While exons are 
essentially rich in G-C nucleotides, A-T content is higher in intronic regions (Amit, Donyo et 
al. 2012). In addition, nucleosomes are positioned more stably in exons flanked by weak 
splice sites than in exons with strong splice sites (Tilgner, Nikolaou et al. 2009). These data 
suggest that nucleosomes, and thereby chromatin structure, may have an effect on 
alternative splicing (Schwartz, Meshorer et al. 2009, Tilgner, Nikolaou et al. 2009). Different 
studies have related nucleosome occupancy with RNAPII elongation rate as well 
(Bondarenko, Steele et al. 2006, Bintu, Ishibashi et al. 2012). Thus, when the polymerase II 
encounters a nucleosome, this generates a transient pause that marks the beginning of each 
exon (Schwartz, Meshorer et al. 2009). This delay will provide more time to the splicing 
machinery for the recognition of weak splice sites.  
In addition to the epigenetic factors described above, different sequences in DNA and 
RNA can promote an RNAPII pausing state. Several studies have associated AT-rich 
sequences with RNA polymerase pausing in bacteria, yeast, and mammals (Artsimovitch and 
Landick 2000, Palangat, Hittinger et al. 2004, Henriques, Gilchrist et al. 2013). Others have 
proposed G-rich termination elements as poly(A) proximal pause sequences that promote 
efficient transcriptional termination (Ashfield, Enriquez-Harris et al. 1991, Gromak, West et 
al. 2006). A well-studied example of pausing elements is the so-called backtracking. This 
phenomenon is based on the reversible movement of RNAPII along DNA and RNA when the 
nascent transcript is displaced from the polymerase active site. This effect prolongs specific 
paused states without depolymerizing the transcript (Sahoo and Klumpp 2013). The RNAPII 
backtracking can be rescued by the TFIIS transcription factor. This protein interacts with the 
active site of the enzyme and promotes the activity of an intrinsic endonuclease to cut and 
excise the backtracked RNA. Once the RNA is cleaved, the 3’ end realigns at the active site 
and transcription can continue (Cheung and Cramer 2011, Nudler 2012). TFIIS protein thus 
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increases RNAPII elongation rate by helping to overcome backtracking (Nudler 2012, 
Pinskaya, Ghavi-Helm et al. 2014). In the end, this transcription factor influences the 
outcome of co-transcriptional splicing by decreasing the window of opportunity during 
which exons can be included.  
 
1.2.4. Cooperation and competition between splicing and polyadenylation machineries 
We have discussed how splicing factors, RNAPII CTD and other related proteins 
regulate alternative splicing and in some cases polyadenylation. However, we have not 
considered that spliceosome and poly(A) machineries are also capable of regulating each 
other. It was described long ago that the U1 snRNP can inhibit the pre-mRNA 
polyadenylation by interacting directly with the poly(A) polymerase (Gunderson, 
Polycarpou-Schwarz et al. 1998). In addition, more recent studies show that this canonical 
spliceosomal factor binds to dormant intronic CstF64 sites to avoid premature 
polyadenylation (Yao, Biesinger et al. 2012). Indeed, U1 impact on the poly(A) machinery has 
been widely studied over the last 10 years, specially by the group of Gideon Dreyfuss. They 
have postulated several times that the U1 snRNP prevents premature cleavage and 
polyadenylation (PCPA), in a process they named Telescripting. Telescripting is necessary to 
maintain long pre-mRNA transcripts (Kaida, Berg et al. 2010, Berg, Singh et al. 2012). Thus, 
U1 levels, apart from controlling the splicing process, has a key role in poly(A) site (PAS) 
usage and therefore in regulating mRNA length. The disruption of this factor promotes an 
extensive usage of more proximal PAS, generating mRNAs with shorter 3’ UTRs. This 
phenomenon is characteristic of activated immune, neuronal and cancer cells (Niibori, 
Hayashi et al. 2007, Flavell, Kim et al. 2008, Sandberg, Neilson et al. 2008, Mayr and Bartel 
2009). 
In addition to shorter mRNAs, the splicing pattern of some genes is indeed affected 
when U1 control is compromised. It is especially important in two different splicing events, 
the so-called bleeding exons and mutually exclusive exons at the 3’ end of genes (Figure 6). 
In both cases, the RNA processing machinery needs to decide between continuing with 
splicing or instead choosing the termination. In those examples, the presence of U1 
suppresses PAS choice, promoting the binding of the U2 snRNP and defining the internal 
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exon (Berg, Singh et al. 2012). Finally, also the RNAPII transcription elongation complex, 
through splicing and poly(A) factor recruitment, has been associated with the regulation of 
both machineries (McCracken, Fong et al. 1997, Hirose, Tacke et al. 1999, Das, Yu et al. 2007). 
 
Figure 6. Splicing (U1 and U2) and polyadenylation (CPA) machineries regulate each other. In bleeding 
exons and mutually exclusive terminal exons, both machineries generate different mRNA variants. U1 
negatively regulates CPA whereas it promotes U2 binding. PAS means polyadenylation site 
 
2. The Death Inducer Obliterator (DIDO) protein 
The death inducer obliterator (Dido) gene was firstly described in 1999 as DIO-1 and 
was associated with the process of apoptosis in pre-B cells from murine bone marrow. 
Initially, only one of three isoforms was identified, and its function was related with the 
induction of apoptosis in vitro and cell death during development (Garcia-Domingo, 
Leonardo et al. 1999, Garcia-Domingo, Ramirez et al. 2003). However, several years later this 
role in apoptosis was found to be a consequence, instead of a cause, of alterations in DNA 
regulation produced by chromatin instability (Rojas, Sanchez-Pulido et al. 2005). Nowadays, 
different phenotypes have been associated with the Dido gene, although finding a specific 
central mechanism is imperative. 
The Dido gene is located on the long arm of chromosome 20 in humans and 
chromosome 2 in mice. It is ubiquitously expressed and contains 16 exons. The gene codes 
for three different proteins generated by alternative splicing, DIDO1, DIDO2 and DIDO3. All 
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isoforms have a common N-terminal region and specific C-terminal parts (Figure 7) 
(Futterer, Campanero et al. 2005).  
 
Figure 7. Representation of the Dido gene and its three different isoforms with the known and predicted 
domains.  
As shared domains, DIDO contains a Nuclear Localization Signal (NLS), and a plant 
homeodomain (PHD) finger and dPHD region (short motif downstream of the PHD domain). 
The latter two domains have been associated with the recognition of post-translationally 
modified H3K4Me3 (Prieto, Kouznetsova et al. 2009). 
The central part of the protein, only shared by DIDO2 and DIDO3, contains a 
transcription elongation factor S-II subunit middle (TFS2M) domain that interacts with 
RNAPII (Futterer, de Celis et al. 2017). The yeast homolog BYE1 uses this domain to recognize 
the RNAPII jaw and funnel domain (Kinkelin, Wozniak et al. 2013). The DIDO TFS2M domain 
corresponds to the second domain of the elongation factor TFIIS that stimulates RNAPII 
transcription through DNA lesions. As we mentioned in previous sections, when RNAPII 
pauses and backtracks during transcription, the TFIIS elongation factor binds to the enzyme 
and enhances RNA cleavage activity. This RNA cleavage promotes the RNAPII escape from 
backtracking (Cheung and Cramer 2011). In addition to the TFS2M region, DIDO2 and DIDO3 
isoforms contain a SPOC (Spen Paralog and Ortholog) domain implicated in protein-protein 
interactions (Sanchez-Pulido, Rojas et al. 2004, Lee and Skalnik 2012). Finally, although little 
is known about the DIDO3-specific exon, the exon 16, it encodes for a large unstructured 
region characteristic for proteins of recent evolution (Haynes and Iakoucheva 2006). This 
kind of disordered sequences have recently been associated with RBP and are thought to 
mediate RNA-protein interactions (Jarvelin, Noerenberg et al. 2016). Although we have not 
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yet identified a specific domain, prediction programs reveal that the exon 16 contains a 
central coiled-coil domain and a carboxy-terminal RNA recognition motif (RRM). 
 Finally, with respect to the location of the three isoforms, DIDO1 distributes over the 
nucleus and cytosol while DIDO2 and DIDO3 are predominantly found in the nuclear 
compartment	(Futterer, Campanero et al. 2005, Trachana, van Wely et al. 2007). Although 
Dido is expressed ubiquitously, DIDO3 expression decreases in somatic cells as compared to 
Embryonic Stem Cells (ESCs), whereas it is recovered in induced pluripotent stem cells (iPSC) 
(Gatchalian, Futterer et al. 2013). 
 
2.1. DIDO as a multifunctional protein  
As mentioned before, Dido was initially associated with apoptosis in immune cells. 
Since 1999, however, a wide variety of studies and mutants have helped to elucidate the real 
functions of the three DIDO isoforms. 
The deletion of the whole Dido in cell lines appears to be incompatible with life. Thus, 
different mutants have been generated by eliminating specific DIDO domains (Figure 8). The 
truncation of the amino-terminal part of DIDO (DidoΔNT) affects the PHD domain. This 
mutation produces aneuploidy, centrosome amplification and cytokinesis defects, all of 
which are related with mitotic spindle alterations	(Trachana, van Wely et al. 2007) . For the 
same reason, the lack of histone binding generates an increased number of lagging 
chromosomes during anaphase, and causes double strand breaks (DSBs) adjacent to 
centromeres (Guerrero, Gamero et al. 2010). All of these defects provoke cell division 
problems and chromosome instability (Martinez and van Wely 2011). Furthermore, mice 
carrying this mutation suffer myeloid neoplasms (Futterer, Campanero et al. 2005), and 
human myeloid leukaemia patients show alterations in DIDO isoform expression. Here, 
DIDO2 expression is increased in advanced phases of the disease (Berzoti-Coelho, Ferreira 
et al. 2016). Finally, using this mutant, DIDO3 has been related with cilium size by regulating 
HDAC6 availability at the centrosome (Sanchez de Diego, Alonso Guerrero et al. 2014).  
Another Dido mutation, which involved the removal of the DIDO3-specific exon 16, 
was generated (Dido3ΔCT). This exon encodes for the carboxy-terminal part of the protein 
and its deletion is lethal at the mouse embryonic stage 8.5 of gestation. The loss of DIDO3 
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produces a delay in the onset of lineage commitment at the stage of primitive endoderm, 
which compromises the differentiation of ESCs. This regulation of stemness genes is 
controlled by the DIDO PHD finger (Gatchalian, Futterer et al. 2013). In the case of in vivo 
models, the differentiation program can be recovered by crossing Dido3ΔCT mice with other 
mutants carrying the ΔNT deletion. These double mutant mice (ΔCT/ΔNT) can survive until 
the end of gestation but show a reduced life expectancy, brain malformations, as well as 
neuromuscular and behavioural alterations (Villares, Gutierrez et al. 2015).  
Finally, the relationship between Dido and histone modifications in mitosis or meiosis 
is another recurrent topic in this protein’s history. The phosphorylation of Histone 3 
Threonine 3 and 6 (H3T3Ph and H3T6Ph) during mitosis correlates with the exclusion from 
chromatin of PHD finger proteins, such as DIDO3, ING1 or TAF3. In the case of DIDO3, the 
protein is expelled from H3K4Me3 at the beginning of mitosis, when chromatin is condensed 
and processes like transcription are suppressed (Gatchalian, Mora Gallardo et al. 2016). This 
exclusion allows DIDO3 to translocate to microtubules and helps to control the mitotic 
spindle (Trachana, van Wely et al. 2007, Gatchalian, Futterer et al. 2013). Besides, the 
H3K4Me3 mark modulates DIDO3 location in meiosis, where it was found at the central 
region of the synaptonemal complex when trimethylation diminished (Prieto, Kouznetsova 
et al. 2009). 
 
Figure 8. Dido mutants lacking the N-terminal or C-terminal part of the protein. 
 
So, as observed, the Dido gene seems to be implicated in many different processes 
and generates a wide variety of phenotypes. These pleiotropic effects likely are related with 
the diversity of domains contained in the three isoforms. The distinct domains allow DIDO 
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to bind multiple proteins and to be part of the regulation of different pathways. However, we 
think that Dido could actually be involved in a more generic and primary process that controls 
and generates different outcomes. Given the interaction with RNAPII and the presence of an 
RRM, RNA metabolism is a good candidate of such a generic process. 
 
2.2. Dido and evolution 
The Dido gene and its products can be found under many different names, from DIO-1 
when first described, to DATF1, C20orf158, BYE1 or PPS. Some of these terms refer to DIDO 
orthologs or homologs. The most studied ones are BYE1, which is expressed in yeast, and 
PPS found in Drosophila melanogaster.  
The BYE1 (Bypass of Ess1) protein is a putative transcription factor identified in 
Saccharomyces cerevisiae. BYE1 contains the same domains found in DIDO1 and DIDO2 
proteins. Its PHD domain interacts with H3K4Me3, favouring enrichment at the actively 
transcribed class II gene promoters. On the other hand, the TFS2M domain interacts with the 
RNAPII jaw (Kinkelin, Wozniak et al. 2013). The PHD domain thus may facilitate RNAPII 
binding by preloading active genes. Although BYE1 is not necessary for cell viability, it 
becomes essential for normal growth or efficient transcriptional activation under stress 
conditions. In these cases, a quick transcriptional response is required, and BYE1 competes 
with TFIIS protein to resume the transcription process (Pinskaya, Ghavi-Helm et al. 2014). 
The PHD, TFS2M, and SPOC domains are very well conserved from human to yeast, not only 
in DIDO but also in the PHF3 protein. The latter has been related with human glioblastoma, 
where its expression is dramatically reduced (Fischer, Struss et al. 2001, Struss, Romeike et 
al. 2001). But, although PHF3 contains a TFS2M domain, its mutated PHD finger impairs 
histone binding	(Gatchalian, Futterer et al. 2013, Pinskaya, Ghavi-Helm et al. 2014).  
While the amino-terminal and central domains of DIDO (DIDO1 and DIDO2) are 
highly conserved in eukaryotes, the C-terminal part of the protein seems to have evolved 
more recently. When generating a phylogenetic tree comparing DIDO, BYE1 and PHF3, we 
observed that the three proteins are classified in different groups (Figure 9). Whereas BYE1 
is found in lower eukaryotes, DIDO and PHF3 are only present in vertebrates. The lampreys 
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seem to fall outside both groups, because they comprise a border between vertebrates and 
invertebrates. This way of grouping indicates that BYE1 (or DIDO2) emerged relatively early 
in evolution. At some point, when the vertebrates showed up and their genome duplicated 
(Kasahara 2007), the DIDO protein evolved individually to acquire a more specialized 
function. The Dido gene included the exon 16 (DIDO3 isoform), allowing for a new role that 
could not be fulfilled by the DIDO1 and 2 proteins.  
 
 
Figure 9. Phylogenetic tree of DIDO 
homologs. The tree was generated 
using ClustalΩ to align the sequences 
and GENEIOUS program to build the 
tree.  
 
 
 
 
 
Along with genomic duplication, vertebrates evolved other important events, such as 
the extensive use of alternative splicing (Iniguez and Hernandez 2017). In contrast to the 
situation in lower eukaryotes, this process became very specialized in higher eukaryotes 
(Keren, Lev-Maor et al. 2010). One exception is the D.melanogaster sex determination gene 
Sex-lethal (sxl). SXL expression is controlled by an autoregulatory alternative splicing 
mechanism. The inclusion of the translation-terminating third exon generates a non-
functional SXL protein in males, whereas this exon is always skipped producing an active 
coding protein in females. The system is autoregulated by SXL itself, by binding to multiple 
intronic sites and to different splicing factors such as the U1 snRNP protein SNF (Sans-fille). 
Another protein implicated in this process is the DIDO homolog, PPS, which interacts with 
SNF and SXL protein, as well as the unspliced Sxl RNA. PPS accumulates at the Sxl promoter, 
favouring the male exon skipping (Johnson, Nagengast et al. 2010).  
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2.3. DIDO and alternative splicing 
 Different evidences seem to relate the Dido gene with RNA splicing. However, only 
the interactions with RNAPII and H3K4Me3 have been documented (Gatchalian, Futterer et 
al. 2013, Kinkelin, Wozniak et al. 2013, Pinskaya, Ghavi-Helm et al. 2014, Futterer, de Celis et 
al. 2017). As we mentioned, the DIDO3 C-terminus is a very disordered sequence and 
although it contains an RRM-like domain, interacting proteins are still unknown. In order to 
identify possible candidates, co-purification experiments were carried out in our laboratory. 
Using a fusion protein formed by glutathione-S-transferase (GST) and DIDO3 without the 
histone-binding domain, several proteins were co-purified along with DIDO itself (Figure 10). 
 
Figure 10. GST pull down experiment using GST fused to DIDO3. GST alone was used as a control and both 
constructs were purified from HEK293T cells and analysed by SDS-PAGE and Coomassie staining (on the left). 
Some of the interacting proteins, initially identified by mass spectrometry analysis, were confirmed by WB (on 
the right). 
 The main interacting protein was SFPQ, a well-documented splicing factor that is 
essential in mammals (Montes, Becerra et al. 2012,Peng, 2002 #115, Peng, Hawkins et al. 
2014). In addition, proteomics analysis identified other proteins, also involved in splicing and 
transcription (DHX9, SRSF7, hnRNP U), and some predominantly nucleolar proteins (NCL, 
NPM). These evidences support the idea that DIDO3 could be implicated in RNA metabolism 
by regulating the alternative splicing process. 
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Another line of evidence derived from evolution reinforces this theory. As we pointed 
out in the previous section, the longest DIDO isoform is only found in organisms that make 
extensive use of AS but not in yeast. Remarkably, invertebrates do not produce SFPQ either. 
Thus, DIDO3 and SFPQ can only be found in vertebrates. Finally, the DIDO homolog PPS is 
implicated in the regulation of SXL alternative splicing in an organism that produces a distant 
SFPQ family member.  
 In conclusion, we already have several indications that DIDO3 is implicated in RNA 
splicing. We will now report a role for the DIDO3-specific domain in SFPQ binding and the 
mechanism followed by DIDO to regulate alternative splicing in mammalian cells.
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1. Study the DIDO3 implication in RNA metabolism through physical interactions with 
splicing factors 
1.1.  Identification of the DIDO isoform involved in the specific interaction with SFPQ 
1.2. Study of the subcellular location of DIDO3 and splicing factors 
1.3.  Analysis of the recruitment failures associated with Dido mutations 
1.4. Study the interaction of DIDO3 with messenger RNA 
2. Characterization of the splicing defects associated to Dido mutations 
2.1. Generation of RNA sequencing data to study the splicing alterations produced by 
Dido mutations  
2.2. Verification of the splicing defects in mouse and human models of Dido mutants 
2.3. Study of the DIDO3 full-length complementation in the recovery of the splicing 
phenotype 
3. Determine the role of the DIDO3-SFPQ axis in alternative splicing regulation 
3.1. Analysis of the molecular mechanism underlying the DIDO3 function in 
alternative splicing related to SFPQ interaction 
3.2. Study of DIDO3-dependent and independent pathways in alternative splicing 
regulation  
3.3. Formulation of a model to explain the role of DIDO3 in alternative splicing linked 
to the transcription process.  
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1. Immortalized cell lines: 
• MEF: Mouse embryonic fibroblast. A type of fibroblast prepared from mouse embryos. In 
this project MEF cell line was generated from C57BL/6 mice and immortalized using 
expression of human papillomavirus E6 and E7. 
• HEK293T: Human cell line generated from HEK293 (Human Embryonic Kidney) with the 
viral antigen SV40 large T. These cells were obtained from the American Type Culture 
Collection (ATCC) (RRID:CVCL_0063). 
• RPE-1: Human cell line derived from the retinal pigment epithelium and immortalized 
with hTERT (RRID:CVCL_4388). 
• HeLa Flp-InTM T-RexTM: Human cell line derived from cervical cancer cells. These 
particular HeLa cells contain the Flp-InTM T-RexTM system (Cat. no. K6500-01) available from 
Thermo Fisher Scientific.  
 The Flp-InTM system allows stable expression of the gene of interest by FLP 
recombinase-mediated integration. The T-RexTM system provides conditional expression of 
the inserted gene under tetracycline or doxycycline induction. HeLa Flp-InTM T-RexTM (HeLa-
FLP) cells include a pFRT/lacZeo (from Flp Recombination Target) and a pcDNA™6/TR (from 
the T-REx™ System) cassettes stably integrated in their genomes. This parental cell line is 
resistant to Zeocin due to the pFRT/lacZeo.  
MEFs and HEK293T cells were cultured in DMEM supplemented with 10% fetal bovine 
serum (FBS), 1% Penicillin/Streptomycin and 1% L-Glutamine. RPE-1 cells were cultured in 
DMEM+F12 (1:1) supplemented with 10% FBS, 1% L-Glutamine and antibiotics. Parental 
HeLa-FLP cells (without the inserted expression cassette) were cultured in DMEM 
supplemented with 10% FBS, 1% Penicillin/Streptomycin, 1% L-Glutamine and 150 µg/ml of 
Zeocin antibiotic to maintain the pFRT/lacZeo cassette. All cell lines were kept in cell culture 
incubators at 37ºC and 5% of CO2. 
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2. Generation of Dido exon 16 mutant cells 
2.1. Generation of MEFs DE16 mutants 
The production of heterozygous Dido exon 16-floxed mice was outsourced (Ozgene 
Ltd, Bentley, Australia). A loxP site was inserted at the 3' end of Dido intron 15, and a 
neomycin cassette, flanked with FLP recombination target (FRT) sites, was inserted 
downstream of Dido exon 16. A second loxP site was inserted downstream, followed by a 
DNA sequence to reproduce the original 3’ SS (See Results, Figure 13). The protein coding 
sequence in the targeting vector was verified. After linearization of the vector and 
electroporation into C57BL/6-derived Bruce4 embryonic stem cells, successful 
recombination was verified by southern blotting of resistant colonies. Correctly targeted 
clones were microinjected into recipient blastocysts for transfer into foster mothers, and 
chimeric offspring were crossed with C57BL/6J mice.  
All subsequent work was carried out at the National Centre for Biotechnology, with 
approval of the local and regional Ethics Committees on Animal Experiments. Mice carrying 
the floxed Dido exon 16 were interbred with UBC-Cre-ERT2 mice (007001, Jackson 
Laboratory, Bar Harbor, ME) and homozygous Dido flox/flox Cre carriers were selected for 
further breeding. MEFs were derived and immortalized as described (Cheng, Luo et al. 2016). 
After treatment with 1 µM hydroxytamoxifen for 2 passages, individual clones were selected 
and genotyped by PCR and WB (See Results Figure 13). Homozygous deletion mutants were 
termed DE16. Primers used for genotyping are described in the Table 1. The DNT mutant 
generation was described before (Prieto, Kouznetsova et al. 2009). 
Primers Sequence (5' -3') 
E16 FLOXED Forward: GTGTGCTGGCACATTCAGGG   Reverse: CGAGTCCGCTTCTCATCTGT 
DE16 Forward: TGCTCGTCAAGAAGACAGGG   Reverse: CGAGTCCGCTTCTCATCTGT 
Table 1. Primers for genotyping the exon 16 deletion in MEF cells. 
 
2.2. Generation of DE16 HeLa Flp-InTM T-RexTM cells  
To generate a human cell line lacking the Dido exon 16, HeLa Flp-InTM T-RexTM cells 
(HeLa-FLP) bearing a single FRT site were targeted with CRISPR-Cas9 (Ran, Hsu et al. 2013). 
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The guides used for specific deletion were designed by Amaia Talavera Gutiérrez. These 
guides are shown in Table 2. After cloning in the pSpCas9(BB)-2A-Puro vector (a gift from 
Feng Zhang, Addgene #62988, Watertown, MA), guides and Cas9 were delivered into HeLa-
FLP cells by transient transfection. Cells were cultured with 1.5 µg/ml puromycin for 72 hours, 
and clones were selected after an additional 2 weeks of growth without selective pressure. 
Correct elimination was verified by PCR with primers shown in Table 3 and by western 
blotting (See Results Figure 27). 
Primers Sequence (5' -3') 
hDido-E16 Guide 1 
Forward: CACCgCCAAGAATTATATTCGGACG 
Reverse: AAACCGTCCGAATATAATTCTTGGc  
hDido-E16 Guide 2 Forward: CACCgAGCGAGACCGGAGGCGCGAC 
Reverse: AAACGTCGCGCCTCCGGTCTCGCTc  
Table 2. Guides used for exon 16 deletion in HeLa-FLP cells. Letters in bold denote Dido sequence. 
Primers Sequence (5' -3')  
WT Forward: TCCTCCTCAGGGTCGTATGG   Reverse: TAAACGTTCCCCGTGAAAGCC 
DE16 Forward: ATGGCTCTAGGGTCCAACGA   Reverse: TAAACGTTCCCCGTGAAAGCC 
Table 3. Primers for genotyping the exon 16 deletion in HeLa-FLP cells. 
 
 
3. Plasmids and constructions 
3.1. V5-tag plasmids for DIDO1, 2 and 3 transient expression 
The three different DIDO isoforms were cloned into a vector containing the V5-tag as 
described (Sanchez de Diego, Alonso Guerrero et al. 2014). A pcDNA3 (Life Technologies) 
plasmid was used for the insertion of the mouse Dido1, Dido2 and Dido3 cDNA at the N-
terminal region. 
3.2. FRT plasmids for DIDO2 and DIDO3 stable expression 
Plasmids for the stable expression of the DIDO2 and DIDO3 isoforms in the HeLa-FLP 
cells were generated by cloning the human cDNA in pcDNATM5-FRT-TO-GFP vectors. This 
plasmid carries the FRT sequence to stably integrate the Dido cDNA within the HeLa-FLP 
genome and an GFP reporter. To generate the DIDO3 plasmid, human Dido3 cDNA from a 
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pcDNA3-HA tag vector (kindly donated by Thierry Fisher, PhD) was amplified using the 
following primers: 
Dido3 Forward: 5’ TGGA GCTAGC GACGACAAAGGCGACCCGAG 3’ 
Dido3 Reverse: 5’ TGGA GCGGCCGC CTAGGCCTGCGAGGCGGTGC 3’ 		 NheI and NotI restriction sites were inserted with the amplification to later clone the 
final fragment in the pcDNA5 vector. This plasmid was named as pcDNATM5-FRT-TO-GFP-
hDido3. 
To produce the DIDO2 plasmid, human Dido2 cDNA was cloned from a pcDNA3-HA-
tag plasmid (kindly donated by Thierry Fisher, PhD) into the previous pcDNATM5-FRT-TO-
GFP vector. In this case, only restriction enzymes were used to insert the sequences instead 
of PCR amplification. The final plasmid was named as pcDNATM5-FRT-TO-GFP-hDido2. 
Both plasmids were later co-transfected with a pOG44 vector containing the Flp 
recombinase for an efficient stable insertion in the HeLa-FLP cells. The Dido inserted 
cassette replaces the Zeocin resistance from the parental cell lines for a Hygromycin 
resistance gene. Positive clones were then selected with 150 µg/ml of Hygromycin B 
antibiotic for 3 weeks. In contrast, negative clones that were still resistant to Zeocin did not 
survive in the Hygromycin supplemented culture. 
3.3. Minigenes 
 To simulate the alternative splicing defect produced between Ndufs7 and Dazap1 
genes in the DE16 mutant, a minigene was generated. The minigene cassette was produced 
in three different modules: two for Ndufs7 and Dazap1 mouse genes and an intermediate one 
including the T-rich motif downstream Ndufs7 or a random sequence. Primers designed for 
the amplification of each module are shown in Table 4. Every primer contained a restriction 
site for the consecutive and proper joining between the modules. Each module was 
generated separately in a pBluescript II SK vector (Addgene #212205) and finally cloned in a 
pcDNATM5-FRT-TO_GFP plasmid.  
The final vectors containing the complete minigenes were co-transfected with a 
pOG44 plasmid into the HeLa-FLP WT and DE16 cells for stable insertion. Minigenes 
expression was induced with 1 µg/ml of doxycycline for 72 hours. 
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Primers Sequence (5' -3') Restriction Sites 
Module 1: 
Ndufs7 
Forward: GC AAGCTT CTACTCGGTTGTTCGTGGCT   
Reverse: GA GAATTC ACCAGAGATGTGTCTTCCGC 
HindIII 
EcoRI 
Module 2.1: 
T-rich motif 
Forward: GA GAATTC TATGTCAGGCCTTCGTGTCC   
Reverse: GA GGATCC AGCTCTTCTTCACTTCGGGC 
EcoRI 
BamHI 
Module 2.2: 
Random seq 
Forward: GA GAATTC GACCCAGTTCTGTTCCCAGC   
Reverse: GA GGATCC AGATCCCTTGGAGCTGGAGT 
EcoRI 
BamHI 
Module 3: 
Dazap1 
Forward: GC GGATCC GGCCACTGCTAAGGTTCTGT   
Reverse: GA ACTAGT GGCTTCGGGTCGATCTATGG 
BamHI 
SpeI 
Table 4. Primers designed for minigene modules generation. “Random seq” means a random sequence. 
Restriction sites are underlined. 
 
4. Immunoprecipitation of DIDO isoforms 
To immunoprecipitate the three DIDO isoforms, the previously described V5-tag 
plasmids were transfected in HEK293T cells. For these transient transfections, 1·106 
HEK293T cells were seeded in 10 cm plates. After 24 hours, 4 µg of plasmid DNA was 
transfected with jetPRIME liposome transfection reagent (Polyplus, Illkirch, France) 
according to the manufacturer´s instructions. Cells were harvested after 72 hours and 
subjected to immunoprecipitation with 2 µg of Rabbit polyclonal anti-V5 antibody (ab9116;	
RRID:AB_307024). DIDO and interacting proteins were pulled down using Protein A 
DynabeadsTM (Thermo Fisher Scientific Inc.) and finally eluted with 1X SDS Sample Buffer 
(60 mM Tris-HCl pH 6.8, 10% Glycerol, 2% SDS, 50 mM DTT, 0.05% Bromophenol). After 
resolving proteins on 8% SDS-PAGE, DIDO and SFPQ were visualized by western blotting 
using a mouse anti-V5 antibody and a rabbit anti-SFPQ, respectively. All antibodies used are 
shown in Table 5. 
Primary antibodies Dilution Supplier company Catalog number 
anti-V5   1:1000 Abcam ab27671, RRID: AB_471093 
anti-SFPQ  1:1000 MBL International RN106PW 
 
Table 5. Antibodies used for membrane development in the immunoprecipitation 
 
5. Immunofluorescence analysis 
For immunofluorescence experiments, cells were grown until 70% confluent, rinsed 
in PBS, fixed in PBS containing 3.7% formaldehyde (FA), and permeabilized in PBS with 0.5% 
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NP40. After blocking in PBS containing 2% bovine serum albumin (BSA) and 0.05% Tween20 
(1 h, room temperature), cells were incubated with primary antibodies (1 h, room 
temperature). Later, cells were washed three times for 10 minutes, incubated with secondary 
antibodies, washed again, and mounted in Prolong Gold antifade containing DAPI 
(Invitrogen). Confocal microscopy was performed using an IX81 microscope (Olympus, 
Tokyo, Japan) with sequential excitation of fluorophores. The antibody against the mouse 
DIDO amino-terminal region (anti-DIDO NT) has been described before (Prieto, 
Kouznetsova et al. 2009). This antibody was raised against a HIS-tagged construct 
containing the mouse DIDO amino acids 2 to 90. All primary and secondary antibodies used 
for immunofluorescence experiments are depicted in Table 6. 
Primary antibodies Dilution Supplier company Catalog number 
anti-SFPQ  1:200 Abcam ab177149 
anti-U2AF1  1:200 Genetex GTX106854, RRID:AB_1952473 
anti-hnRNP U  1:200 Abcam ab20666, RRID:AB_732983 
anti-human DIDO (N-terminal)  1:200 Abcam ab92868, RRID:AB_10562305 
anti-human NDUFS7  1:200 ABGENT AP20502C  
anti-mouse DIDO (DIDO NT) 1:100 Lab production - 
Secondary antibodies Dilution Supplier company Catalog number 
Goat anti-Mouse IgG Cy3  1:400 Jackson 115-166-071 
Goat anti-Rabbit IgG Alexa 488  1:200 Molecular Probes A-11034 
Table 6. Antibodies used in immunofluorescence experiments for human and mouse cell lines 
To efficiently inhibit transcription elongation, RPE-1 cells were treated overnight with 
500 µg/ml of Actinomycin D (A9415, Sigma, St. Louis, MO). To impair the splicing process 
and complex B formation, RPE-1 and MEF cells were treated overnight with 40µM of 
Isoginkgetin (416154, Merck Millipore). Both treatments were used as described elsewhere 
(Shav-Tal, Blechman et al. 2005, Huranová, Ivani et al. 2010). Besides, in both cases, vehicle 
cells were treated with DMSO.  
 
The ImageJ package (rsbweb.nih.gov/ij) was used for image processing and 
measurements. For measurement of supramolecular complexes when MEFs were treated 
with IGK, contrast optimized images were binarized in ImageJ using watershed 
segmentation	(Soille and Vincent 1990) before particle size analysis. Around 100 different 
cells were analysed to generate statistics. Representative images are shown in all figures. 
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6. Proximity ligation assay 
Nuclear interaction between SFPQ and DIDO3 was detected using Duolink® In Situ 
Orange Starter Kit Mouse/Rabbit (DUO92102, Sigma), according to the manufacturer´s 
instructions. The protocol was carried out as follows. MEFs were cultured on glass coverslips 
until 50% confluent. Cells were washed once in PBS, fixed with 3.7% FA (10 minutes), and 
washed again in PBS. Cells were permeabilized with 0.5% NP40 (5 minutes) and blocked 
using the provided blocking solution (1 hour, 37°C). After incubation with primary antibodies 
against DIDO and SFPQ (Table 7) for 1 hour at room temperature, two proximity ligation 
probes were added and incubated (1 hour, 37°C). DNA was amplified by adding polymerase 
and complementary fluorescent nucleotides (90 minutes, 37°C). Coverslips were mounted 
on Superfrost ultra plus microscope slides (Thermo Fisher Scientific, Waltham, MA) in the 
provided mounting medium, and visualized as described for immunofluorescence. 
Primary antibodies Dilution Supplier company Catalog number 
anti-SFPQ  1:200 Abcam ab177149 
anti-mouse DIDO (DIDO NT)  1:100 Lab production - 
anti-RNAPII CTD (8WG16)  1:200 Abcam ab817 
Table 7. Primary antibodies used for Proximity Ligation Assay 
 To quantify the number of hotspots, 3D Object Counter plug-in from ImageJ 
(rsbweb.nih.gov/ij) was used. Around 20 cells were selected from each sample to measure 
the interactions. First, a low number of cytoplasmic dots were extracted from the picture. 
Once only the cell nuclei was selected, the 3D Object Counter plug-in quantified the total 
number of dots. In parallel, the area of every cell nucleus was measured for each counted cell. 
Finally, the number of dots were normalized to each cell area and statistical analysis were 
performed using a two-tailed Welch´s t-test comparing WT with both Dido mutants.  
7. Western Blot 
 Protein samples were obtained from WT, DE16 and DNT MEFs cells using a 1X SDS 
Sample Buffer (60 mM Tris-HCl pH 6.8, 10% Glycerol, 2% SDS, 50 mM DTT, 0.05% 
Bromophenol) supplemented with complete protease inhibitors (04693132001, Roche 
Applied Science). Proteins were resolved on 8% SDS-PAGE and transferred to a PVDF 
membrane. Antibodies used for Dido mutants detection are shown in Table 8. An antibody 
that recognizes specifically the mouse Dido exon 16 was generated in our lab and named as 
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anti-DIDO CT.	This antibody was raised in rabbits against a peptide corresponding to the 
carboxy-terminal amino acids 1392 to 1410 of mouse DIDO3 (AFHTLLAEPGRPHDVQSVS). 
Primary antibodies Dilution 
Supplier 
company Catalog number 
anti-Tubulin  1:2000 Abcam ab44928, RRID:AB_2241150 
anti-DIDO NT (N-terminal)  1:500 Lab production - 
anti-DIDO CT (C-terminal)  1:500 Lab production - 
Table 8. Antibodies used for MEF DE16 verification. 
8. RNA sequencing 
WT, DE16 and DNT MEFs were grown to 80% confluence, washed once in PBS, and 
lifted by trypsinization. After washing again with PBS, total RNA was isolated from 
approximately 5·106 cells with a SPLIT RNA extraction kit (Lexogen, Austria) using the 
manufacturer´s protocol. For each mutant and the WT control, biological triplicates were 
prepared. Subsequent steps were outsourced to on-campus facilities (Parque Cientifico de 
Madrid). A Bioanalyzer (Agilent) was used to measure RNA quality and all samples used had 
RNA integrity numbers (RINs) of 9 or higher. Libraries were prepared from 1 µg total RNA by 
the TruSeq RNA v2 method (Illumina) and at least 50 million paired-end (2x100) reads per 
sample were obtained on a HiSeq 2000 system (Illumina). 
9. RNA sequencing analysis 
Sequencing adaptors were removed from both ends of the reads. Obtained 
sequences were aligned with Tophat2 (version 2.1.0) against the Mus musculus mm10 
assembly	(Daehwan Kim, Pertea et al. 2013) using the corresponding gene annotation model 
to guide alignment of splice junctions. Initial classification of splicing alterations was 
performed by Altanalyze software (Emig, Salomonis et al. 2010). The fragcount script from 
the RSeQC package (Huang, Li et al. 2012) was used to determine expression levels. To 
quantify exon skipping, the number of junctions spanning each exon was counted and 
divided by the corresponding expression (in FPKM) normalized to gene level. Some 
intergenic junctions were found, but these were not used for 3’SS or sequence motif 
identification. Using gene-level expression allows for quantitation of exons that are always 
skipped in one of the samples. Altered exons were identified as those that were significantly 
different (p<0.05) in a two-tailed t-test comparing triplicate Dido mutant samples to the 
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same number of WT controls. For 3’ SS usage, junctions mapping within 3 bases of known 
exon boundaries were analysed, and normalized according to the total number of junctions 
sharing the 5’ SS but not coinciding on the same 3’ SS. Altered usage was defined as a 
significant difference (p<0.05) of the ratio between the sampled and alternative 3’ SS, in a 
two-tailed Welch´s t-test comparing WT and mutant triplicates. Since the t-test is 
intrinsically conservative and our data showed a large degree of interdependence, no p-value 
correction was carried out.  
10. Reverse-transcriptase PCR 
Total RNA was isolated as described for RNA sequencing. Reverse-transcriptase PCR 
amplifications on 1 µg total RNA were performed using a Verso One-step RT-PCR Kit 
(Thermo Fisher Scientific Inc.) according to the manufacturer’s instructions. To analyse 
splicing alterations, several set of primers were used to amplify specific regions of Gas2L1, 
Fat1, Wdr8, Ndufs7 and Dazap1 mouse transcripts. An additional set of primers was used to 
amplify the human Gas2L1, Spata7, Ndufs7 and Dazap1 genes. All primers are depicted in 
Table 9 and 10. 
Primers Sequence (5' -3')  
mGas2L1 Long Isoform Forward: AAGCATGACCCTTGTCGCTG    Reverse: GAGGCTGAGGAGTCACTGTC 
mGas2L1 Short Isoform Forward: AAGCATGACCCTTGTCGCTG    Reverse: CAAACCCCAGAAGCCTGGAAA 
mFat1 Exon inclusion Forward: GTCAGAATGGAGGCGTTTGC   Reverse: GCAGAGGACGAACACCATCA 
mFat1 Exon skipping Forward: GGTGCTGTCTGTCAGTGTGA    Reverse: GCAGAGGACGAACACCATCA 
mWdr8 cUTR Forward: GCTGTTTGTGGTACTAGAGC    Reverse: AGACAGAAGTGGTCCTTACT 
mWdr8 aUTR Forward: GCTGTTTGTGGTACTAGAGC    Reverse: TGCCTTAAATGTGCTGTCAA 
mNdufs7 gene Forward: GCTATGTGGTGTCCATGGGG    Reverse: CACGCTTGATCTTCCGTTGC 
mDazap1 gene Forward: CGCCGACGAAATCGGGA        Reverse: TTTGCTGCTGTCGCTCCTG 
mNdufs7-Dazap1 Fusion  Forward: GCTATGTGGTGTCCATGGGG    Reverse: TTTGCTGCTGTCGCTCCTG 
mNdufs7 minigene Forward: GGTTGTTCGTGGCTGTGACC    Reverse: TTCACGCTTGATCTTCCGTTG  
mDazap1 minigene Forward: GCCTGGACTGGAGTACCACT    Reverse: TCTAGGGTGTGTGGTCTGCT  
mNdufs7-Dazap1 Fusion  Forward: GGTTGTTCGTGGCTGTGACC   Reverse: TCTAGGGTGTGTGGTCTGCT  
 Table 9. Primers used for Reverse transcriptase PCR amplification of mouse genes. 
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Primers Sequence (5' -3')  
hGas2L1 Long Isoform Forward: GCTACTCCGGGGACAGTGAC    Reverse: ATGAGTGCTGCCCGTCTCG 
hGas2L1 Short Isoform Forward: TTCCAGCTCCTCCGATGAAG    Reverse: CGTGAGGGTTTACGGTCTGG 
hSpata7 gene Forward: GAGCAACCTCTGTCCTTCCC    Reverse: GCTTACTGGAACCGAGCAGT 
hNdufs7 gene Forward: ACGGAGGAGGCTACTACCAC   Reverse: CCGAGGGCAGGTTTATTGAC 
hDazap1 gene Forward: CAAGAGACTCTGCGCAGCTA    Reverse: CTGTTATCGCTCCTGGGTCC 
hNdufs7-Dazap1 Fusion  Forward: ACGGAGGAGGCTACTACCAC    Reverse: CTGTTATCGCTCCTGGGTCC 
Table 10. Primers used for Reverse transcriptase PCR amplification of human genes. 
11. Real Time quantitative PCR (RT-qPCR) 
Total RNA was isolated as described for RNA sequencing with the SPLIT RNA 
extraction kit (Lexogen, Austria) and quantified using NanoDrop. The Transcription First 
Strand cDNA Synthesis Kit (04896866001, Roche Applied Science) was used to obtain the 
cDNA from 1 µg of isolated RNA in a BioRad Themocycler. RT-qPCR reactions were carried 
out in MicroAmpTM Optical 384-Well Reactions with Barcode (#4309849, Applied 
Biosystems). A master mix of primers (shown in Table 11 and 12) and 5X HOT FIREPol 
EvaGreen qPCR Mix Plus (ROX) (Solis BioDyne) was added to the amplified cDNA. The 
equipment used for quantitative PCR was an ABI PRISM 7900 HT (Applied Biosystems). The 
conditions for the RT-qPCR reaction were: 5 min at 95ºC, 40 cycles of 15 seconds at 95ºC and 
60 seconds at 60ºC. A final dissociation step was added.  
 The relative quantification of each gene was calculated using the Expression Suite 
Software (Thermo Fisher Scientific Inc.) and based on the CT values. These values were 
generated by using the fluorescence increase data and the number of cycles obtained from 
the equipment. The CT values were corrected using housekeeping genes to calculate a DCt 
value. Finally, this number was compared between WT and mutant samples (DDCt) and the 
relative quantification (RQ) value was generated using the equation 2-(DDCt). This RQ number 
was represented in every graph applying a logarithmic scale. 
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Primers Sequence (5' -3')  
mGas2L1 Long Isoform Forward: AAGCATGACCCTTGTCGCTG    Reverse: GAGGCTGAGGAGTCACTGTC 
mGas2L1 Short Isoform Forward: AAGCATGACCCTTGTCGCTG    Reverse: CAAACCCCAGAAGCCTGGAAA 
mFat1 Exon inclusion Forward: GTCAGAATGGAGGCGTTTGC   Reverse: GCAGAGGACGAACACCATCA 
mFat1 Exon skipping Forward: CACTGGTCAGAGATGTCAGAGT    Reverse: GCAGAGGACGAACACCATCA 
mWdr8 cUTR Forward: GCTGTTTGTGGTACTAGAGC    Reverse: AGACAGAAGTGGTCCTTACT 
mWdr8 aUTR Forward: GCTGTTTGTGGTACTAGAGC    Reverse: TGCCTTAAATGTGCTGTCAA 
mNdufs7 gene Forward: GCTATGTGGTGTCCATGGGG    Reverse: CACGCTTGATCTTCCGTTGC 
mDazap1 gene Forward: CGCCGACGAAATCGGGA        Reverse: TTTGCTGCTGTCGCTCCTG 
mNdufs7-Dazap1 Fusion  Forward: GCTATGTGGTGTCCATGGGG    Reverse: TTTGCTGCTGTCGCTCCTG 
mRPL32 Forward: TTAAGCGAAACTGGCGGAAAC    Reverse: TTGTTGCTCCCATAACCGATG  
mbeta 2 microglobulin (b2M) Forward: GCCTGTATGCTATCCAGAAAACCCC    Reverse: TGAGGCGGGTGGAACTGTGT  
mTPT1 Forward: CATCAGCCATGACGAGCTGTT    Reverse: CTCTGTTCTACTGACCATCTTGC  
Table 11. Primers used for RT-qPCR amplification of mouse genes. RPL32, b2M and TPT1 were housekeeping 
genes. 
 
Primers Sequence (5' -3')  
hDido2 Forward: ACAGGCACGTCAAGGACCTC    Reverse: AGAAAGCCGGCGCTTACC 
hDido3 Forward: ACTCTTGCCCTTTGAGGGACCA    Reverse: TCGGGTCCGCTTTTCGTCCA 
hNdufs7 gene Forward: ACGGAGGAGGCTACTACCAC   Reverse: CCGAGGGCAGGTTTATTGAC 
hDazap1 gene Forward: CAAGAGACTCTGCGCAGCTA    Reverse: CTGTTATCGCTCCTGGGTCC 
hNdufs7-Dazap1 Fusion  Forward: ACGGAGGAGGCTACTACCAC    Reverse: CTGTTATCGCTCCTGGGTCC 
hHPRT Forward: GGAAAGAATGTCTTGATTGTGGAAG    Reverse: AAGGAACCAGTCCGTCATATTAGG  
hbeta actin Forward: AGCGAGCATCCCCCAAAGTT    Reverse: GGGCACGAAGGCTCATCATT  
hGAPDH Forward: AGAAGGCTGGGGCTCATTTG    Reverse: AGGGGCCATCCACAGTCTTC  
Table 12. Primers used for RT-qPCR amplification of human genes. HPRT, b actin and GAPDH were 
housekeeping genes. 
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12. Photoactivatable Ribonucleoside - Enhanced Crosslinking and 
Immunoprecipitation (PAR-CLIP) 
MEF WT, DE16 and DNT samples were used for the PAR-CLIP experiments that were 
carried out as described (Hafner, Landthaler et al. 2010). Cells were cultured in 2 x 15 cm 
dishes until reaching 80-90% confluence and treated overnight with 100 µM 4-Thiouridine 
(4SU). After two PBS washes, samples were placed on ice and irradiated with 0,15 J/cm2 UV 
light at 254 nm as previously described. Once mRNA-proteins were crosslinked, cells were 
harvested and lysed on Lysis Buffer (20 mM Tris-HCl pH 7.5, 500 mM LiDS, 0,5% LiDS, 1 mM 
EDTA and 5 mM DTT) and then homogenized using a 27G needle. At this step, an input was 
taken and the negative control was treated with RNAse A. To capture the Poly (A) mRNA-
protein complexes, samples were incubated with oligo(dT)25 magnetic beads (NE Biolabs) 
for 1 hour at 4°C with gentle rotation. Afterwards, these beads were washed with buffers 
containing decreasing concentrations of LiCl and LiDS. Then, mRNA-protein complexes 
were eluted by RNAse A treatment for 30 minutes at room temperature. With this step, 
mRNAs were eliminated and only the crosslinked proteins remained. Finally, SFPQ was 
detected by western blot using an anti-SFPQ antibody (RN106PW, MBL International) and 
the protein levels were measured using ImageJ software and “Gels” plug-in. 
13. Individual - nucleotide resolution Crosslinking and Immunoprecipitation 
(iCLIP) 
MEF WT, DE16 and DNT cells were cultured in 2 x 15 cm dishes. Here, the iCLIP 
protocol was performed as described	 (Ule, Jensen et al. 2003). After reaching 80-90% 
confluence, cells were washed with PBS, placed on ice, and irradiated with 0,15 J/cm2 UV light 
at 254 nm. Then, cells were lysed using Lysis Buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 
0,5% NP40, 0,1% SDS, 0,5% sodium deoxycholate and 1 mM DTT) and partially digested with 
1:250 RNAse I dilution for 3 minutes at 37°C and 500 rpm shaking. Once the reaction was 
stopped with RNAse inhibitors, an input sample was taken and the rest was 
immunoprecipitated using Protein A DynabeadsTM (Thermo Fisher Scientific Inc.). SFPQ was 
precipitated with a polyclonal antibody (RN106PW, MBL International, Woburn, MA) and an 
isotype was used as negative control. After 1 hour of 4°C incubation, beads were washed 
several times in buffers with decreasing salt concentration. Samples were digested with 
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Proteinase K and total RNA was isolated with the SPLIT RNA extraction kit (Lexogen, 
Austria) using the manufacturer´s protocol. A Bioanalyzer (Agilent) was used to measure 
RNA length and quality. Finally, RT-PCR amplifications were performed using a Verso One-
step RT-PCR Kit (Thermo Fisher Scientific Inc.) with a pair of primers designed for Gas2L1 
gene detection (Table 13). 
Primers Sequence (5' -3')  
mGas2L1  
Forward: TCACTGTCCCCAGAGTAGCG    
Reverse: CCGCGCCAGTGATACACATC 
Table 13. Primers designed for Reverse Transcriptase PCR amplification of mouse Gas2L1 iCLIP RNA. 	
 A different version of the iCLIP technique was carried out in order to validate DIDO3 
binding to the RNA. This modification involved the RNA labelling using an EZ-LinkTM HPDP-
biotin reagent (Thermo Fisher Scientific Inc.). Similar to the PAR-CLIP technique, cells were 
treated with 100 µM 4-Thiouridine (4SU), until reaching 80-90% confluence, and crosslinked 
with 0,15 J/cm2 UV light at 254 nm. After cell lysis, inputs samples were taken and total RNA 
was labelled with 50µl of EZ-LinkTM HPDP-biotin (4mM stock), that reacts to the thiol group 
contained in the 4SU. RNA-protein complexes were immunoprecipitated using Protein G 
DynabeadsTM (Thermo Fisher Scientific Inc.) with the anti-DIDO NT antibody (ab92868, 
abcam, RRID:AB_10562305) and Protein A DynabeadsTM (Thermo Fisher Scientific Inc.) with 
the anti-SFPQ antibody (ab177149, abcam). After 1 hour of 4°C incubation, beads were 
washed several times in buffers with decreasing salt concentration and RNA-protein 
complexes were eluted using 1X SDS Sample Buffer (60 mM Tris-HCl pH 6.8, 10% Glycerol, 
2% SDS, 50 mM DTT, 0.05% Bromophenol). Finally, after resolving proteins on 8% SDS-
PAGE, RNA-protein complexes were visualized using a fluorescent eFluor710 streptavidin 
conjugate. Input membranes were developed with anti-DIDO NT and anti-SFPQ antibodies. 
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Chapter 1. DIDO C-terminal interactions suggest a role in RNA metabolism 
1.1. DIDO-SFPQ interaction is mediated through the DIDO3/exon 16 
 As mentioned in the introduction, GST pull down experiments showed that DIDO3 
interacts with several splicing factors. The main interactor was SFPQ (PSF), a known SF 
associated with PPT binding (Patton, Porro et al. 1993). To test what DIDO isoform was 
involved in the SFPQ interaction, we co-immunoprecipitated the DIDO proteins after 
expression in HEK293T cells. V5 tag plasmids were used to overexpress the individual DIDO 
isoforms. Membranes developed with an anti-SFPQ antibody revealed that only DIDO3, the 
longest isoform, interacts with SFPQ (Figure 11). 
 
 
 
 
 
 
Figure 11. DIDO-SFPQ interaction is specific for the 
DIDO3 isoform. HEK293T cells were transfected with 
three plasmids bearing a V5 tag fused to mouse DIDO1, 2 
or 3 isoforms. Even though the expression of V5-DIDO3 
was lower than the other isoforms, and SFPQ levels are 
equal in all samples, WB revealed specific co-precipitation 
of SFPQ with DIDO3 longest isoform.               
 
 
 
 
 
 
 
 
 
 
 
The results of the co-immunoprecipitation (Co-IP) supported the mass spectrometry 
analysis of the GST pull down, confirming the interaction between SFPQ and DIDO3. In 
addition, these data delimit SFPQ binding to the DIDO protein region corresponding to exon 
16. 
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1.2. DIDO protein co-localizes with splicing factors when cells are treated with different 
RNA metabolism inhibitors  
 Most accessory splicing factors, such as SFPQ, have a function in positioning of 
spliceosome subunits on the nascent mRNA. However, only a small proportion of these co-
localizes with other SF when splicing is proceeding normally. This is due to the dynamic 
behaviour of the spliceosome, where splicing factors are continuously recycled for their 
utilization in new complexes (Chen and Manley 2009, Kornblihtt, Schor et al. 2013). Small 
molecule inhibition of RNA metabolism has been widely used to interfere with this process. 
For example, Actinomycin D (Carmo-Fonseca, Pepperkok et al. 1991) acts by suppressing 
topoisomerases and transcription elongation (Sobell 1985). We thus evaluated the role of 
DIDO3 in the splicing process by studying SFPQ and DIDO distribution in the presence or 
absence of Actinomycin D (Figure 12). Confocal scanning laser microscopy was used to 
visualize the proteins. 
 
 
Figure 12. Actinomycin D treatment produces co-localization of SFPQ and DIDO at subnuclear domains. 
RPE-1 cells were seeded on coverslips and treated with vehicle (CTL) or 5 μg/ml of Actinomycin D overnight. 
First row shows the merge of three colours while second and third rows depict a colour separation of SFPQ and 
DIDO labelling respectively. The antibody against H. sapiens DIDO recognises the N-terminal part (DIDO NT), 
so it labels the three isoforms. Boxed areas show magnification of single nuclei. Scale bar, 10 μm.  
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 While barely any co-localization was found in the control cells, DIDO and SFPQ 
accumulated at the same subnuclear domains after Actinomycin D treatment. This 
accumulation at nuclear speckles is typical of known splicing factors (Carmo-Fonseca, 
Pepperkok et al. 1991), which supports the idea that DIDO3 is involved in RNA metabolism. 
 Nevertheless, Actinomycin D can interfere with transcription and therefore with 
RNAPII recycling (Shandilya and Roberts 2012). We therefore used Isoginkgetin (IGK), an 
inhibitor that specifically affects the splicing process. IGK interferes with the U4/U6-U5 tri-
snRNP recruitment to the spliceosome in vitro. As a consequence, the pre-spliceosome A 
accumulates and the U1 and U2 snRNP remain attached to the pre-mRNA, impairing their 
recycling (Behzadnia, Golas et al. 2007, O'Brien, Matlin et al. 2008, Huranová, Ivani et al. 
2010). Not only SFPQ (Figure 13A) but also U2AF1 factor (Figure 13B) co-localized with 
DIDO in large subnuclear domains after IGK treatment. However, another splicing factor 
such as hnRNP U was not contained at these patches (Figure 13C).  
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Figure 13. Splicing inhibition produces the accumulation of some splicing factors and DIDO at subnuclear 
domains. RPE-1 cells were seeded on coverslips and treated overnight with vehicle (CTL) or 40 μM of 
Isoginkgetin (IGK). (A) The first row shows the merge of three colours. The second and third rows depict a colour 
separation of DIDO NT and SFPQ labelling, respectively. (B) In this case, cells were labelled with U2AF1 and 
DIDO NT antibodies. (C) The first column shows the merge of three colours while second and third column 
depict DIDO and hnRNP U respectively. (A,B) Boxed areas show magnification of single nuclei. Scale bar, 10 
μm. 
 
  
 These results show that DIDO, as well as SFPQ and U2AF1, is affected by splicing 
inhibition and changes its distribution in the cell nucleus by accumulating at typical 
		 77	
subnuclear domains. Unlike hnRNP U, both SFPQ and U2AF1 are involved in the correct 
positioning of the U2 snRNP on the 3’SS (Gozani, Patton et al. 1994). Based on protein 
localization, we hypothesize that the role of DIDO could be related with this step of 
spliceosome formation. 
 
1.3. Dido mutants modulate IGK-dependent SFPQ distribution 
 Based on the DIDO3-SFPQ interaction and the IGK results, we asked whether this 
splicing inhibitor would also alter the SFPQ distribution in cells carrying Dido mutations. So, 
in order to test this hypothesis, Mouse Embryonic Fibroblast (MEF) cell lines lacking the 
entire exon 16 (ΔE16) or the N-terminal part (ΔNT) of the gene were used (Figure 14).  
 
 
Figure 14. Representation of Dido mutations generated in Mouse Embryonic Fibroblasts (MEFs). Blue 
segments represent the region shared by the three DIDO isoforms, green depicts the central part of the protein, 
shared by DIDO2 and DIDO3 isoforms, and the carboxy-terminal part specific for the DIDO3 protein is shown 
in red colour. This C-terminal region corresponds to the Dido exon 16. 
 
While Dido ΔNT mutants were made by homologous recombination (Futterer, 
Campanero et al. 2005), the Dido ΔE16 cells needed to be generated using a conditional 
strategy. Embryonic lethality was avoided by making the latter mutant with the Cre-LoxP 
system (Figure 15A). To obtain MEFs without the exon 16,	a mouse strain bearing this exon 
flanked by loxP sites was interbred with Cre-ERT2 producing mice. The resulting embryonic 
fibroblasts were then isolated from the second-generation offspring. After 10 days of 
treatment with 4-hydroxytamoxifen, MEFs lacking Dido exon 16 were obtained and mutation 
was confirmed by PCR and WB experiments (Figure 15B and 15C). 
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Figure 15. Generation of MEFs lacking Dido exon 16. (A) Schematic representation of exon 16 targeting and 
deletion strategy; (B) PCR confirmation of targeting (floxed/floxed; fl/fl) and deletion (Δ/Δ) of mouse Dido exon 
16; (C) Western Blot confirmation of the deleted protein (ΔE16) using both DIDO antibodies, anti-DIDO NT that 
recognizes the N-terminal part of the protein and anti-DIDO CT that binds specifically to aminoacids encoded 
by the exon 16. Tubulin was used as a loading control and ΔNT mutant as a negative control for the DIDO NT 
antibody. 
 
After obtaining both mutants, we decided to evaluate the effect of these Dido 
mutations on SFPQ distribution when splicing is affected. Thus, SFPQ location was studied 
by immunofluorescence after treating Dido WT, Dido ΔE16 and Dido ΔNT MEFs with IGK 
(Figure 16). 
These analyses showed a speckled pattern corresponding to SFPQ distribution in MEF 
cells treated with IGK. This nuclear distribution is typical for SFPQ under conditions in which 
splicing is disrupted (Shav-Tal, Blechman et al. 2005) and already occurred in RPE cells 
(Figure 13A). However, whereas these subnuclear domains measured several square 
micrometers, Dido mutations seemed to reduce their size as compared to WT samples. In 
both mutants, especially in Dido DE16, IGK had little effect on SFPQ redistribution and most 
of the protein was located in smaller speckles (Figure 16B). 
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Figure 16. Dido mutations reduce the size of supramolecular complexes after IGK treatment. MEF WT, ΔE16 
and ΔNT cells labelled with anti-SFPQ antibodies were treated with vehicle or 40 µM Isoginkgetin (IGK). (A) 
Representative immunofluorescence images of control (upper row) and treated cells (lower row). (B) 
Quantification of supramolecular complex sizes with and without IGK treatment in WT and mutant cells. The 
IGK treatment produced less supramolecular (>2.5 µm2) structures in Dido mutants as compared to WT 
controls. 
 
1.4. Dido mutation affects SFPQ recruitment 
The previous data show that DIDO3/exon 16 controls SFPQ subnuclear distribution. To 
address whether Dido mutations could also alter SFPQ recruitment to the splicing 
machinery, Proximity Ligation Assays (PLA) were performed. In this technique, a 
quantifiable fluorescence signal is emitted when two proteins are interacting or at least 
closer than 40 nm (Weibrecht, Leuchowius et al. 2010). Thus, PLA experiments to quantify 
the DIDO3 and SFPQ interaction and detect possible recruitment problems were carried out 
with both Dido mutants. We included a first negative control with a single antibody to 
measure the background signal. In addition, the DNT mutant acted as an additional negative 
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control since the anti-DIDO NT antibody recognises the deleted region of this mutant. Both 
controls showed a low number of scattered PLA signals, confirming the validity of the 
technique. On the contrary, substantial interaction between both proteins was observed in 
WT MEFs (Figure 17A). Despite equal SFPQ expression in all samples (Figure 17C), the 
removal of exon 16 (Dido DE16) prevented PLA signal formation (Figure 17A). Further 
quantification of the PLA signals confirmed significant differences between WT and DE16 
mutant MEFs (Figure 17B). 
 
Figure 17. DIDO3/exon 16 is necessary for SFPQ binding and recruitment. (A) Immunofluorescence images 
of Proximity ligation assays between SFPQ and DIDO. Red spots represent proximity between both proteins, 
while nuclei are depicted in blue. The control sample was labelled with only one antibody, while ΔNT MEFs 
lacks the DIDO antibody epitope. ΔE16 MEFs lack the DIDO3 carboxy-terminal region that interacts with SFPQ. 
Proximity signals of DIDO and SFPQ were detected in WT but not in ΔE16 MEFs. (B) PLA signal quantitation 
revealed significant proximity loss in both mutants. Error bars represent standard deviation (SD). ***p<0.001. 
(C) WB of SFPQ protein levels in WT and mutant MEFs. Tubulin was used as a loading control. 
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Together, these results links the DIDO3 isoform to SFPQ recruitment and distribution 
at the cell nucleus. The distribution of DIDO3 is also affected by splicing inhibitors and follows 
SFPQ, implicating the protein in spliceosome formation at the U2 snRNP-positioning step. 
We therefore conclude at this point that DIDO3 is related to the splicing process, a hitherto 
undefined role for this protein. We thus designed experiments to further characterize this 
novel role, which are described in the next chapters. 
 
1.5. DIDO as an RNA binding protein (RBP) 
We explained in the introduction that DIDO3 contains a predicted RRM (RNA 
recognition motif) that is encoded within exon 16. Since similar domains are commonly 
found in RBP and splicing factors (Haynes and Iakoucheva 2006), DIDO3 not only could be 
implicated in the splicing process via SFPQ interaction but also through a direct binding to 
the RNA molecule. In addition, recent publications describing the RNA interactome included 
the DIDO protein in a long list of RBP candidates (Baltz, Munschauer et al. 2012, Castello, 
Fischer et al. 2012). In order to confirm DIDO3 binding to the nascent RNA molecule, we 
applied the PAR-CLIP technique.  
PAR-CLIP is based on crosslinking by ultraviolet light and addition of a photoreactive 
uridine analogue named 4-thiouridine (4SU). The 4SU is inserted into nascent RNA during 
transcription. Subsequent UV irradiation at 254 nm generates a crosslink between RBPs and 
the RNA molecules. These mRNA-protein complexes are covalently bound, so pulling down 
the messenger RNAs using oligo (dT) beads allows us to isolate and analyse the associated 
RBPs (Castello, Horos et al. 2013).  
To harness this technique for DIDO3, HEK293T cells were treated with 100 μM 4SU 
for 24 hours and subsequently UV irradiated. After cell lysis, the combination of messenger 
RNA and associated proteins was pulled down using oligo (dT) beads. Finally, through an 
RNAse treatment to remove all RNA molecules, RBPs were eluted and loaded on a protein 
gel to detect DIDO3 (Figure 18A). Nonirradiated cells incubated with 4SU were used as 
negative control. Despite seeing DIDO2 and DIDO3 in the inputs, we were not able to detect 
any protein in the crosslinked samples. The SFPQ control yielded a signal after crosslinking, 
showing effectiveness of the pull-down (Figure 18B). 
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Figure 18. iCLIP but not PAR-CLIP experiments suggest RNA binding by DIDO3. (A) Schematic 
representation of the PAR-CLIP technique. HEK293T cells were grown until 50% confluence and treated for 24 
hours with 100 µM 4SU. When they reached 90% confluence, cells were irradiated with 0,15 J/cm2 UV light at 
254 nm and lysed. After capture using oligo (dT) beads, the proteins were eluted with RNAse A, and DIDO and 
SFPQ were detected by SDS-PAGE. (B) Western Blot detection did not find co-precipitation of DIDO with 
messenger RNAs. Negative control samples were not UV irradiated and SFPQ detection was used as a positive 
control. (C) Schematic representation of the iCLIP technique. HEK293T cells were grown as described above. 
When they reached confluence, cells were irradiated with 0,15 J/cm2 UV light at 254 nm and lysed. Then, RNA 
was marked with EZ-link HPDP-biotin. After immunoprecipitation, Protein-RNA complexes were separated by 
SDS-PAGE and RNA was detected with a fluorescent streptavidin conjugate. (D) Protein membranes show 
representative images of three different experiments. Output membranes were developed with an 
streptavidine-eFluor710 antibody to label the biotinylated RNA. Input membranes were developed with anti-
DIDO NT (left) and anti-SFPQ (right) antibodies. Experiments correspond to the DIDO (left) and SFPQ (right) 
immunoprecipitations. Due to partial RNA degradation, a smear is observed above the protein band only in the 
UV irradiated samples. The smear is typical from RNA-protein complexes in both cases. An asterisk in the SFPQ 
output membrane indicates a possible SPFQ oligomerization or dimerization. 
 
Since several proteins may compete for RNA in a PAR-CLIP, iCLIP was used to directly 
precipitate the target proteins (Figure 18C). In contrast to the PAR-CLIP experiment, iCLIP 
produced a typical smear in the crosslinked samples but not in the controls. This smear 
corresponds to partially degraded RNA covalently bound to the precipitated RBPs. The 
presence of a smear above DIDO3 thus indicates direct interaction with RNA (Figure 18D). 
Several factors, for example the proportion of interacting DIDO3 and protein stability, could 
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influence this alternative outcome; the epitope detected by the antibody used is located far 
from the predicted RRM and some protein degradation was evident in all DIDO samples. 
Both factors might have a greater impact on PAR-CLIP as compared to iCLIP. 
Although one of these methods suggests DIDO3 binding to RNA, conclusive evidence 
is still missing. Thus, all subsequent experiments were based on the hypothesis that DIDO3 
has a role on the splicing process through SPFQ interaction. 
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Chapter 2. Dido mutations generate splicing defects 
2.1. Different splicing alterations appear when Dido is mutated 
To confirm the hypothesis that DIDO3 is implicated in RNA splicing, mutant MEFs 
lacking the N-terminal part (DNT) and exon 16 (DE16) were subjected to RNA sequencing. 
Triplicate samples of at least 50 million paired reads were analysed and compared to MEFs 
from WT littermates. Initially, we confirmed that the deleted region did not show residual 
RNA sequencing reads in the mutants (Figure 19). 
 
 
Figure 19. RNA sequencing shows no residual reads in the Dido exons targeted for deletion (arrows). 
Representative MEF clones are shown for WT and each mutant in the IGV viewer. Read density is depicted in 
grey and splicing events are connected by clear blue lines. Exons are represented as dark blue boxes and introns 
are shown as blue lines. 
 
 
 In order to identify splicing changes and knowing that several of the DIDO3-
interacting proteins act in splice site selection, a first general classification of alternative 
splicing events was performed with the Altanalyze software (Emig, Salomonis et al. 2010). 
This analysis identified a large number (around several thousand) of splicing events that 
significantly differed between Dido mutants and WT controls (Figure 20A). The majority of 
these alterations involved exon skipping or exon inclusion, although a smaller subset 
corresponded to different events including alternative 5’ or 3’SS selection. Although most of 
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these changes have already been described in the literature or databases, a smaller 
percentage corresponds to novel events only visualized in our Dido mutants. When 
considering each mutant separately, DE16 has a preference for exon skipping events while 
the DNT mutant favoured exon inclusion. 
 
Figure 20. Dido mutations generate several thousand of splicing alterations. (A) General classification of the 
altered splicing events found in the mutants compared to the WT MEFs. Most of them (>60%) correspond to 
exon-level changes, such as exon skipping or exon inclusion. Yellow colour shows events already included in the 
databases, while purple boxes represent alterations not yet described. (B) Principle component analysis of 
altered splicing events distinguished WT, DNT, and DE16 groups. 
 
Once we classified the alternative splicing events, a Principal Component Analysis 
(PCA) was performed to measure the relationship between the three sample groups. The 
results from this analysis produced three distinct groups, which corresponded to WT, DNT 
and DE16 samples (Figure 20B). Both mutants were displaced along one axis compared to 
WT controls (PC1), but only DNT moved up along the second axis (PC2). This separation 
indicates that both mutants share some qualities but at the same time produce unique 
alterations. Additionally, we quantified the levels of exon skipping with respect to WT 
controls in both mutants (Figure 21A). The volcano plots show that DNT mutants favour a 
situation of less skipping while DE16 samples bear widespread alterations encompassing 
exon skipping and inclusion. In the latter mutant, the most significant events are related with 
an increase in exon skipping. Finally, DNT and DE16 samples were compared in a Venn 
diagram depicting the significant events from the volcano plots (Figure 21B). With this 
comparison, we found that sizable exon populations suffer from the same alterations in both 
mutants but also uncovered many differences. 
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Figure 21. Each mutant favours different types of splicing alterations. (A) Volcano plots show exon skipping 
events in both mutants compared to WT. Increased skipping is depicted to the right of the vertical axis and 
decreased skipping to the left. The dotted line corresponds to the cut-off used for selection of significant 
events. (B) Venn diagram comparing exon skipping differences between mutants.  
 
 In order to confirm the RNA sequencing results, diverse subsets of exons were verified 
by real time quantitative PCR (RT-qPCR). In this thesis project, we will show four different 
examples that are representative of significant splicing alterations discovered by the massive 
sequencing (Figure 22,23,24 and 25). 
 The first example is the Fat-1 gene. This member of the cadherin superfamily has a 
role in cellular polarization, in cell-cell contact, and in directing cell migration. In addition, it 
has been recently associated with the modulation of the epithelial-mesenchymal transition 
(EMT) and regulation of stemness genes in human cancer (Srivastava, Irshad et al. 2018). 
Based on our previous analysis, we located one internal exon that was commonly skipped in 
all samples. RNA sequencing showed that this exon was skipped significantly more in the 
DE16 mutant than in the WT sample (Figure 22A). Reverse transcriptase PCR and RT-qPCR 
confirmed the changes in exon skipping between samples (Figure 22B and C). 
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Figure 22. DIDO3/exon 16 deletion increases exon skipping in the Fat-1 gene. (A) Sashimi plot of Fat-1. 
Expression coverage is shown in colour while splicing is represented by curved lines. White boxes denote exons 
and straight lines are introns. (B) Reverse transcription PCR experiments were performed to verify primer 
specificity. (C) RT-qPCR was used to quantify changes in exon skipping and inclusion. The first graph shows 
relative quantification comparing each mutant with WT samples. The second graph illustrates skipping 
differences between the three samples. Both graphs depict relative quantification values on Log 2 scale. Error 
bars represent SD from three different experiments. 
 
 A second example was found in the Gas2L1 gene. This protein binds to microtubules 
and actin filaments, playing an essential role in centriole motility and centrosome disjunction 
(Au, Jia et al. 2017). GAS2L1 contains two different isoforms generated by alternative 
splicing. Although the WT sample produces the shortest transcript, a longer splice variant is 
generated when the last exon is skipped. This long transcript is highly enriched in both 
mutants while it is barely expressed in the WT sample (Figure 23). Interestingly, we found 
that the DE16 mutant favoured the expression of “downstream” transcripts in GAS2L1 and 
other similar examples. In all these cases, the constitutive and upstream exon was always 
skipped to include an alternative and downstream exon, usually generating different 
isoforms. Although this effect was also detected in DNT MEFs, differences were not as big as 
those found in the DE16 mutant. 
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Figure 23. Dido mutants favour last exon skipping in Gas2L1 gene. (A) Sashimi plot of Gas2L1. Expression 
coverage is shown in colour while splicing is represented as curved lines. White boxes denote exons and straight 
lines are introns. Upper scheme corresponds to the long isoform while the one below represents the short 
isoform. (B) Reverse transcription PCR experiments were performed to verify the primer specificity. (C) RT-
qPCR was used to quantify both isoforms. The first graph shows relative quantification comparing both 
mutants with WT samples. The second graph illustrates the expression of the long transcript compared to the 
shorter one in all samples. Both graphs depict relative quantification values on Log 2 scale. Error bars represent 
SD from three different samples. *p<0.05; **p<0.01. 
 
 The Wdr8 gene provided the next example. This WD repeat-containing protein acts 
as a regulator of spindle anchoring to the mitotic centrosome. A recent study described that 
WDR8 indeed is necessary for centrosome assembly in living vertebrate embryos (Inoue, 
Stemmer et al. 2017). The Wdr8 gene contains a constitutive 3’ UTR (cUTR) that generates 
the functional and complete WDR8 protein in WT controls. In both of our mutants, however 
splicing followed a different pattern. Here, splicing from the penultimate exon to an 
intergenic region downstream the constitutive 3’UTR was detected (Figure 24). This isolated 
region fits with the idea of an alternative 3’UTR (aUTR), as it contains some of the usual 
sequences for polyadenylation sites. In addition, NCBI databases report a non-coding RNA 
sequence that corresponds to this alternative UTR. 
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Figure 24. Dido mutants promote the use of an alternative 3’UTR by the Wdr8 gene. (A) Sashimi plot of 
Wdr8. Expression coverage is shown in colour while splicing is represented as curved lines. White boxes denote 
exons and 3’UTRs, and straight lines are introns. (B) Reverse transcription PCR experiments were performed to 
verify primer specificity. (C) RT-qPCR was used to quantify mRNA containing the constitutive UTR (cUTR) or 
the alternative UTR (aUTR). The first graph shows relative quantification of both isoforms, comparing each 
mutant with WT samples. The second graph illustrates the expression of the aUTR compared to the cUTR in all 
samples. Both graphs depict relative quantification values on Log 2 scale. Error bars represent SD from three 
different samples. *p<0.05; **p<0.01; ***p<0.001. 
 
Finally, our analyses identified a series of events that are rare under normal 
conditions, fusion messenger RNAs generated by transcription from two consecutive genes. 
In the last example, Ndufs7 and Dazap1 are two genes located in tandem on the same 
chromosome. NDUFS7 is a core subunit of the respiratory chain NADH dehydrogenase in the 
mitochondrial membrane (Hyslop, Duncan et al. 1996) and DAZAP1 is an RNA binding 
protein involved in mammalian development and spermatogenesis (Tsui, Dai et al. 2000). 
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Figure 25. Dido DE16 mutant generates a fusion messenger RNA between the consecutive genes Ndufs7 
and Dazap1. (A) Sashimi plot of Ndufs7 and Dazap1. Expression coverage is shown in colour while splicing is 
represented as curved lines. Splicing events between first and second Dazap1 exons are not depicted in order 
to emphasise the intergenic splicing. White boxes denote exons and 3’UTRs, and straight lines are introns. (B) 
Reverse transcription PCR experiments showed amplification of the fusion mRNA. (C) RT-qPCR was used to 
quantify the mRNA from both genes and the fusion transcripts. In the first graph, we compared the level of 
each transcript in mutants to WT samples. The second and third graphs illustrate the amount of fusion relative 
to expression of each of the genes involved. The three graphs depict relative quantification values on Log 2 
scale. Error bars represent SD from three different samples. **p<0.01; ***p<0.001. 
 
We discovered that some splicing occurred from the penultimate exon of Ndufs7 to 
the second exon of Dazap1, albeit only in the DE16 mutant. This aberrant splicing fused the 
messenger RNAs from both genes and generated a continuous transcript with shared 
regions. Using Reverse transcriptase PCR experiments, we confirmed the presence of this 
fusion mRNA. RT-qPCR quantified the frequency at which the fusion was produced in all 
samples (Figure 25). 
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2.2. Gene ontology analyses show an activation of the interferon-related response in 
Dido mutants 
 Once all splicing alterations were analysed, we asked whether gene expression was 
also affected and whether a specific pathway could be assigned to the effect of Dido 
mutations. Thus, Gene Ontology (GO) enrichment analyses and clustering were performed 
(Figure 26). GO enrichment showed altered expression of several pathways related to the 
interferon response. It seems that both Dido mutants display a coordinated regulation of 
interferon-stimulated genes, that has been associated with the cellular response to aberrant 
RNAs (Zevini, Olagnier et al. 2017).  
 
 
Figure 26. Dido mutations produce an increase in the interferon-related responses. GO analysis were 
performed using the Altanalyse program. Three replicates of each sample were included to obtain statistical 
power. The pathways showing significant enrichment or depletion were ordered according to the calculated p-
value (left). The pathways associated with the interferon-related response were labelled with an asterisk. 
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2.3. Deletion of exon 16 in human cells produced splicing alterations similar to those 
found in mouse embryonic fibroblasts 
 In order to further study the role of DIDO3 in different contexts and bearing 
translational experiments in mind, we moved on to human cells. Since the majority of and 
the more varied splicing alterations were found in the DE16 mutant, we decided to generate 
a comparable mutation in a human cell line. We choose the human line HeLa Flp-InTM T-
RexTM (HeLa-FLP) stable cell line that contains a Tet-on system; these cells allow the 
introduction of a single copy of exogenous DNA into the HeLa genome, mimicking a 
relatively physiological situation for transgene expression. When desired, doxycycline 
supplementation induces the homogeneous expression from the introduced cassette.  
In order to study the effect of DIDO3 deletion on these HeLa-FLP cells, we generated 
the corresponding mutation using the CRISPR/cas9 system. Since the deletion of exon 16 
produced the strongest effects in mouse cells, we only reproduced this mutation. Design and 
cloning of the RNA guides were performed by Amaia Talavera, according to the described 
protocol (Ran, Hsu et al. 2013). The pSpCas9(BB)-2A-Puro vector, containing the Cas9 
enzyme, was used for sgRNA cloning and transfection into the HeLa-FLP cell line. After 
selection with 2 μg/ml Puromycin for 48 hours, clones were genotyped to confirm correct 
exon 16 deletion (Figure 27).  
 Once mutant cells were obtained, we studied whether the same splicing alterations 
found in MEFs also occurred in the human cell lines. Thus, the Gas2L1 gene already studied 
in mouse cells (Figure 23) and other susceptible candidates such as Spata7 were selected. In 
the mouse Spata7 gene, WT cells promoted inclusion of one of two mutually exclusive exons, 
while the DE16 mutants favoured inclusion of the other one (data not shown). We thus 
hypothesized that Spata7 could suffer from the same kind of alterations in our mutant 
human cells. Indeed, the DIDO3/exon 16 deletion in humans favours exon skipping in the 
Spata7 gene and the selection of the longest transcript in the Gas2L1 gene (Figure 28). 
Similar to the situation in the mouse mutants, all skipped exons form part of non-canonical 
transcripts. 
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Figure 27. Generation of HeLa-FLP cell lines lacking Dido exon 16 by CRISPR/Cas9. We confirmed the 
elimination of the C-terminal region in several clones by PCR (A) and Western Blot (B) techniques. To validate 
absence of DIDO3, we used the anti-DIDO NT antibody that recognises the N-terminal part of the protein. 
Three different clones are depicted in (A) while a representative image of one clone is shown in (B). (C) 
Immunofluorescence analysis of HeLa WT and DE16 cells labelled with DAPI and anti-DIDO NT antibody. Scale 
bar, 5 µm. 
 
 
 
Figure 28. Deletion of Dido exon 16 in human cells reproduces splicing alterations. (A) The Gas2L1 gene in 
human cells presents two isoforms generated by alternative splicing. While the short transcript is equally 
expressed in WT and DE16 samples, the long transcript can only be found in the mutant . The blue boxes 
represent the exons implicated in alternative splicing. (B) Spata7 exon skipping events are increased in the DE16 
mutants compared to the WT cells. The blue box depicts the skipped exon. 
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Another example is the fusion transcript generated between the consecutive genes 
Ndufs7 and Dazap1. In our DE16 mouse mutants, splicing from the last exon of Ndufs7 to the 
second exon of Dazap1 was found. These alterations produced a fusion transcript containing 
regions of both genes. We therefore asked whether our human mutants would trigger the 
same fusions. Surprisingly, a fusion transcript was generated but splicing started in an 
upstream region as compared to the fusion in the mouse samples. Here, splicing was initiated 
from the penultimate exon instead of the last exon of Ndusf7. And although little signal was 
found in the WT samples, it seemed that more fusion transcript was generated by the DE16 
cells (Figure 29). 
 
Figure 29. Fusion transcripts are also produced in HeLa-FLP DE16 mutant cells. The blue boxes represent 
the skipped exons and the blue line depicts the splicing event that generates the fusion transcript. Expression 
levels of Ndufs7 and Dazap1 are equal in both samples while the fusion transcript seems to be generated more 
frequently in the DE16 mutant. 
 
 
Interestingly, the splicing events in the human mutants gave rise to an in frame fusion 
of Ndufs7 and Dazap1 exons, so the fusion transcript could be translated into a fusion protein. 
In order to test the generation of this protein, western blot and immunofluorescence 
analyses were performed (Figure 30). As expected, only the DE16 cells produced a fusion 
protein that was detectable with an anti-NDUFS7 antibody (Figure 30A). In addition, 
immunofluorescence experiments showed an antibody signal that was not exclusively 
located in the cytoplasm, although NDUFS7 is considered a cytoplasmic protein. In the exon 
16 mutants, NDUFS7 signal was distributed more between the cytoplasm and the nucleus 
(Figure 30B). Since DAZAP1 is a nuclear protein, we believe that the fusion protein was 
targeted to the nucleus instead of being exported to the mitochondria. 
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Figure 30. The Ndufs7-Dazap1 fusion transcript produces a fusion protein with shared properties. (A) 
Western blot of WT and DE16 HeLa-FLP cells developed with anti-NDUFS7 (upper box) and anti-tubulin (lower 
box). We detected the NDUFS7 signal at around 20 kDa and an additional band at approximately 70 kDa only 
in the DE16 mutant. This upper band could correspond to the fusion protein formed by NDUFS7 (20 kDa) and 
DAZAP1 (50 kDa). Tubulin was used as a loading control. (B) Immunofluorescence experiments labelling 
HeLa-FLP samples with anti-NDUFS7 (green), anti-DIDO NT (red) and DAPI (blue). The NDUFS7 signal was 
mostly cytoplasmic in the WT cells but distributed between the nucleus and the cytoplasm in the DE16 mutants. 
The absence of DIDO3 signal in the C-terminal mutant confirmed exon 16 deletion. Scale bar, 25 µm. 
 
These data show that the lack of exon 16 in human cells results in alternative splicing 
defects similar to those found in MEFs. In some cases, such as the Ndufs7 and Dazap1 
intergenic splicing, not only a fusion transcript but also a fusion protein is produced. 
Moreover, this fusion protein is even capable of modifying the normal location of the 
NDUFS7 protein, implying that the splicing alterations can have a global effect. 
 
2.4. Complementation with full-length DIDO3 restores the normal splicing metabolism 
in human cells 
Since human Dido mutants showed splicing alterations comparable to mouse cells, 
we tested if complementation experiments with the full-length protein would revert this 
effect. As mentioned before, HeLa-FLP cells allow stable integration of exogenous DNA and 
induction of its expression by doxycycline. Thus, the full-length human Dido3 cDNA (hDido3) 
was cloned in a pcDNATM5-FRT-TO-GFP vector and integrated in DE16 cells. Vice versa, we 
wanted to study whether saturation of the RNA polymerase II interaction through the TFS2M 
domain could affect RNA metabolism and therefore the splicing process. Thus, a 
complementary plasmid containing the human Dido2 cDNA (hDido2) was generated, to 
overexpress this isoform in WT cells.  
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 After obtaining clones, the expression of both proteins (DIDO2 and DIDO3) was 
induced with 1 µg/ml Doxycycline for 72 hours. Immunofluorescence analyses were used to 
detect GFP fused proteins in HeLa-FLP WT and DE16 cells (Figure 31A). Although the 
expression was not entirely homogeneous, most cells expressed the full-length DIDO3 
isoform. In the case of DIDO2, the expression was lower than DIDO3 even though the same 
induction time was applied. However, the real expression levels measured by RT-qPCR do 
detect the overproduction of both human DIDO2 and DIDO3 isoforms in complemented cells 
(Figure 31B). 
 
Figure 31. hDIDO2 and hDIDO3 overexpression in human HeLa-FLP cells. (A) HeLa-FLP cells were 
transfected with plasmids containing eGFP fused to human DIDO2 or DIDO3. Immunofluorescence 
experiments were performed to evaluate expression of eGFP fusion constructs. Although widespread 
expression of exogenous hDido3 was found in the DE16 mutant, hDIDO2 induction was not as intense as 
expected. Scale bar, 25 µm. (B) Quantification by RT-qPCR of hDIDO2 and hDIDO3 expression levels in all 
samples. Graphs depict relative quantification values on Log 2 scale. In both cases, the primer pair not only 
detects the endogenous gene but also the inserted one. Error bars represent SD from three different samples. 
*p<0.05; ***p<0.001. 
 
 To test whether the splicing alterations were reverted by stable DIDO3 expression in 
our DE16 cells, we measure the levels of the Ndufs7-Dazap1 fusion transcript. After correcting 
for expression of the endogenous genes, expression of the fusion transcript was significantly 
reduced in exon 16 mutants complemented with DIDO3. Interestingly, overexpression of 
DIDO2 increased fusion transcript levels compared to WT controls, although this effect was 
mild as compared to exon 16 absence (Figure 32). 
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Figure 32. Complementation with full-length DIDO3 protein in DE16 mutants partially restores the normal 
splicing behaviour. (A) Reverse transcriptase PCR of Ndufs7, Dazap1 and fusion transcripts in parental and 
complemented cell lines. (B) RT-qPCR analysis of all samples. The first graph depicts the comparison between 
the expression levels of the Ndufs7 gene and the fusion transcripts. The second graph represents the same 
comparison but using the Dazap1 gene. In both cases, DE16 mutant shows higher fusion levels, while DIDO3 
complementation promotes normal Ndufs7 and Dazap1 expression. Both graphs depict relative quantification 
values on Log 2 scale Error bars represent SD from three different samples. *p<0.05; ***p<0.001. 
 
 
To check SFPQ accumulation in nuclear speckles, the parental and complemented 
HeLa-FLP cells were treated with the Isoginkgetin (IGK) inhibitor (see Results Chapter 1.2). 
As observed previously, immunofluorescence experiments showed SFPQ accumulation in 
supramolecular complexes in WT cells treated with this splicing inhibitor (Figure 33A). The 
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proportion of large complexes was reduced in the human DE16 cells. Nevertheless, after 
DIDO3 complementation, speckle amount increased to the WT levels and the phenotype was 
restored. On the other hand, overexpression of DIDO2 in WT cells diminished the generation 
of these SFPQ complexes to levels found in the DE16 mutants (Figure 33B). 
 
 
 
Figure 33. Complementation of DIDO3 
in DE16 mutants restored the 
accumulation of SFPQ in 
supramolecular complexes. (A) 
Immunofluorescence of HeLa-FLP cells 
labelled with anti-SFPQ (red) and 
treated with 40 µM IGK shows the 
formation of supramolecular complexes 
(arrows). DIDO2 and 3 isoforms are 
depicted in green due to the eGFP 
expression. Representative images are 
shown. Scale bar, 10 µm. (B) 
Measurements of SFPQ accumulation in 
supramolecular complexes. The 
introduction of DIDO3 in HeLa-FLP DE16 
mutants restored the WT phenotype, 
while expression of DIDO2 in a WT 
background prevented complex 
formation. 
 
  
 
 
 
 
 
 
 
In conclusion, the combination of splicing alterations and reduced SFPQ 
accumulation in supramolecular complexes was confirmed in human DE16 cells. In addition, 
complementation with the full-length DIDO3 isoform mostly restored the WT phenotype, 
confirming the specificity of the alterations related to the lack of DIDO3. 
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Chapter 3. The DIDO3-SFPQ axis regulates alternative splicing  
3.1. Dido mutations reduce SFPQ binding to mRNA 
The human model was a very useful tool for complementation approaches and the 
confirmation of the relationship of DIDO3 to splicing alterations. However, MEFs allow us to 
work with both types of DIDO3 mutants and to broaden our vision of the DIDO3 role in the 
splicing process. In particular, the DNT and DE16 mutations correspond to different protein 
domains in DIDO3. 
Previous results showed that SFPQ is tightly linked to DIDO3. Since Dido mutation 
modulated the effect of splicing inhibitors on SFPQ recruitment and distribution, the same 
mutations could also compromise SFPQ interaction with RNA. To evaluate this hypothesis, 
PAR-CLIP experiments as described (Castello, Horos et al. 2013, Takeuchi, Iida et al. 2018) 
were carried out in MEF cells. We crosslinked SFPQ to the mRNA, isolated the protein-RNA 
complexes using oligo (dT) beads and quantified the amount of SFPQ recovered from every 
sample (Figure 34). Compared to WT MEF, SFPQ levels were markedly reduced in DE16 
samples and moderately diminished in DNT mutants. Negative controls showed barely any 
signal (Figure 34A). Quantitation of three independent PAR-CLIP experiments revealed that 
Dido exon 16 deletion significantly reduced the SFPQ binding to the RNA molecules (Figure 
34B). 
 
Figure 34. Dido mutations reduce SFPQ binding to mRNA. (A) Representative image from three independent 
PAR-CLIP experiments with MEF samples. After crosslinking, polyadenylated RNA molecules and the 
associated RBPs were isolated. Eluates were loaded into a SDS-PAGE acrylamide gel and separated by 
molecular weight. Membranes from Inputs and IP samples were developed with an anti-SFPQ antibody. (B) 
SFPQ recovery was measured by the quantification of band intensity from three PAR-CLIP experiments. The 
quantifications were performed using Image J software. All numbers were normalized to the WT intensity 
(100%). Error bars represent SD from three different samples. **p<0.01. 
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 After confirming the effect of Dido mutations on SFPQ binding, we tested SFPQ 
recruitment to specific genes. In this case, Crosslinking and Immunoprecipitation (CLIP) 
experiments were carried out following a previously described protocol (Ule, Jensen et al. 
2003). Here, RNA-protein complexes were photocrosslinked using UV irradiation and SFPQ 
protein was immunoprecipitated. After protein digestion, the associated RNAs were 
extracted and quantified using a Bioanalyser (Figure 35A). Finally, to identify targets but 
avoid cDNA library construction, we searched a CLIP-Seq experiment published and 
available online (Takeuchi, Iida et al. 2018). Once the SFPQ peaks were cross-referenced with 
our altered genes, we selected one of the most affected genes regarding alternative splicing, 
Gas2L1. Thus, primers for the specific amplification of the exon boundaries corresponding to 
the SFPQ peak were designed (Figure 35B). A reverse transcriptase PCR (RT-PCR) was used 
to amplify the RNA extracted from inputs and immunoprecipitated samples. A band of 
correct size for the Gas2L1 gene was obtained in all inputs. While the WT outputs showed 
the same band, no amplification was produced by the Dido mutants (Figure 35C). These 
results confirmed the defect of SFPQ recruitment to the mRNA when DIDO3 is absent.  
Since extensive splicing alterations were found in the DE16 mutant and to a lesser 
degree in the DNT mutant, we asked whether the exons affected by these alterations 
correlated with SFPQ binding deficiency. To further evaluate the SFPQ occupancy on the 5’ 
end of alternatively spliced exons, the published SFPQ CLIP-Seq data was used (Takeuchi, 
Iida et al. 2018). We define occupancy as the coverage in CLIP-Seq output corrected for 
expression level (derived from inputs). First, a list of the significantly altered exons in both 
Dido mutants as compared to WT was generated. Next, the SFPQ occupancy in these exons 
was compared to a random unaltered population (Figure 36A). Exons affected by altered 
splicing in DE16 or DNT mutants showed a significantly higher SFPQ occupancy with respect 
to the random population. In addition, SFPQ occupancy was related to the type of alternative 
splicing event; we found a positive correlation between exon skipping and the presence of 
an SFPQ peak. In contrast, exons prone to inclusion showed less SFPQ occupancy (Figure 
36B).  
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Figure 35. SFPQ-dependent exons are affected by Dido mutations. (A) Bioanalyser results showing the 
length and quantity of the RNA extracted from SFPQ CLIP experiment. The vertical axis represents RNA 
concentration measured in fluorescence units (FU). The horizontal axis represents the length of the recovered 
RNAs. We obtained detectable amounts of RNA, 50-100 nucleotide in length, from all samples except the 
negative control (C0). (B) Schematic representation of the mouse Gas2L1 gene including the iCLIP-Seq analysis 
(Takeuchi, Iida et al. 2018). Control (CTL) and IP data show specific SFPQ peaks at the Gas2L1 gene (black 
arrow). Primers designed for CLIP amplification are shown in colours. (C) While reverse transcriptase PCR 
produced a band in the WT sample no Gas2L1 amplification was found in both Dido mutants. Representative 
picture from three different experiments.  
 
 
Together, these results confirm that exons regulated by SFPQ are the ones more 
alternatively skipped in DE16 and DNT mutants. Thus, the lack of DIDO3 reduces SFPQ 
binding to messenger RNA, affecting the splicing of a group of susceptible exons. 
Furthermore, exons with similar SFPQ occupancy tend to be more included in the DNT 
mutant but more skipped in DE16. 
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Figure 36. Exons significantly more skipped in both Dido mutants correlate with SFPQ occupancy. (A) 
Quantification of SFPQ binding to a random control group or to altered exons in both Dido mutants. **p<0.01. 
Error bars represent standard error of the mean. (B) Positive correlation between SFPQ occupancy and 
individual exons that are skipped significantly more or less in DE16 and DNT mutants as compared to WT. 
 
 
3.2. Dido mutations alter the preference for upstream 3’SS 
 According to SFPQ dependence, exons respond differently to Dido mutations. 
Whereas DNT increased the exon inclusion events, DE16 mostly gave rise to exon skipping 
(Figure 20). Since SFPQ is involved in the proper recognition of the 3’SS at an early stage of 
the spliceosome assembly (Gozani, Patton et al. 1994), we studied whether the use of these 
3’SS indeed differed between the mutants and the WT. In order to test this hypothesis, we 
first designed a scheme of alternative splicing events in which multiple 3’SS, upstream and 
downstream, share a common 5’ donor site (Figure 37A). Based on this scheme, the 
utilization of each 3’SS relative to the alternative sites was calculated. The name “utilization” 
thus defines the contribution of one 3’SS to the splicing system, measured on a scale from 0 
to 100%. According to the designed scheme, the 3’SS were grouped by distance relative to 
the common 5’SS, more upstream or downstream than alternative acceptor sites. 
 First, we found that in a random set of unaltered 3’SS (or exons), 80% of the splicing 
originated from the upstream 3’SS whereas only 10% used the downstream site (Figure 37C). 
This effect was expected, as it follows the “first come, first served” model (Aebi and 
Weissmann 1987). However, when we calculated WT utilization for the 3’SS of exons that are 
affected in Dido mutants (altered 3’SS), we saw that their behaviour was different. On 
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average, upstream sites in affected exons were used less than downstream 3’SS. Thus, exons 
that will be affected in the Dido mutants already show more exon skipping than unaltered 
exons in WT cells (Figure 37B and C).  
 
Figure 37. Dido mutants change the normal preference for 3’SS utilization. (A) Schematic representation of 
the formula used for utilization calculation. For each 3’SS, the contribution to splicing (utilization) was 
compared to the alternative sites. (B) The horizontal axis represents the distance of the alternative and the 
original 3’SS to a common 5’SS. If distance “a” is smaller than distance “b” in panel A, the 3’SS is located 
upstream and vice versa. The vertical axis represents utilization in WT cells of a random group of 3’SS (dotted 
line) and utilization in WT cells of 3’SS that are significantly (p<0.05) altered in DE16 and DNT mutants (coloured 
lines). (C) Comparison of all upstream and downstream 3’ SS shows that the differences are significant for the 
population as a whole. Error bars depict standard deviation. ***p<0.001. 
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Figure 38. Dido mutations modulate intrinsic preference for upstream 3’SS (A, B) In these graphs, the 3’SS 
that were significantly altered in both mutants are separated into two groups. Graphs show WT utilization and 
mutant utilization for each group. The group that is used more by the mutants is depicted in green and the 
group that is used less is depicted in orange. Continuous lines represent the WT utilization while the 
discontinuous lines depict the mutant values. Arrows in both graphs illustrate the effect of 3’SS usage in DNT 
and DE16 mutants compared to WT. (C) Differentiation of upstream 3’ SS used significantly more or 
significantly less in each mutant. (D) Differentiation of downstream 3’ SS used significantly more or significantly 
less in each mutant. Error bars depict standard deviation. ***p < 0.001. 
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Nevertheless, if both mutants are analysed separately, information regarding the real 
use of upstream and downstream 3’SS can be extracted. So, we divided the list of 
significantly (p<0.05) altered 3’SS in the mutants (depicted in Figure 37B) into two groups. 
One group of 3’SS was used more and the other less as compared to the WT samples. Finally, 
WT and mutant utilization values were calculated for each 3’SS in each group. These four lists 
were represented in Figure 38A (DNT) and B (DE16).  
One of first things that we noticed is that both mutants behaved very differently. 
Taking a look at the arrows, DNT increased utilization of a group of 3’SS that are used 
frequently in the WT (Figure 38A, green lines). Likewise, this mutant decreased utilization of 
a group of 3’SS that are used infrequently in the WT (Figure 38A, orange lines). In contrast, 
DE16 increased utilization of a group of 3’SS that are not often used in the WT (Figure 38B, 
green lines) and supressed 3’SS that are used commonly (Figure 38B, orange lines). 
 Since upstream 3’SS are frequently used in the WT (Figure 37), the DNT mutant 
favours exon inclusion. On the other hand, the DE16 mutant favours exon skipping, a 
tendency that we already confirmed in the cases of the Gas2L1 and Wdr8 genes (Figure 23 
and 24). These differences were quantified and the changes in both populations were 
significant (Figure 38C and D). The differences in 3’SS utilization also explained the number 
of exons that are included or skipped in both mutants (Figure 21). 
 
3.3. Splice site composition does not influence exon usage 
Since splicing alterations in Dido mutants are related to the use of individual 3’SS, the 
next step was the study of the splice site sequence. To test this parameter, we generated a 
WebLogo representation of differentially used splice sites in DE16 and DNT mutants (Figure 
39). Both 3’SS and 5’SS sequences were drawn and compared to a randomized selection of 
unaltered splice sites. In contrast to what we expected, the composition of the splice sites 
showed no correlation with 3’SS utilization. In nearly all the cases, no significant differences 
were recognized between mutants and the random population.  
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Figure 39. 5’ or 3’SS composition shows no correlation with exon usage in both mutants. (A, B) Weblogo 
representations of 3’ acceptor site (A) and 5’ donor site (B) of differentially used exons in DNT and DE16 
mutants. For 3’SS calculations, we included the PPT sequences. No significant differences were found in any of 
the cases.  
 
 
3.4. Downstream sequence motifs modulate exon skipping and inclusion 
 Since splice site composition itself was not implicated in differential exon usage in our 
mutants, surrounding sequences might influence the splicing alterations. It has been 
published that regional nucleotide content and short recognition motifs for different splicing 
factors can modulate splicing in higher vertebrates (Goren, Ram et al. 2006, Amit, Donyo et 
al. 2012). In order to study the former, we analysed whether the nucleotide composition 
surrounding alternatively spliced exons in our Dido mutants had any bias (Figure 40). Using 
a random selection of unaltered exons as control, we observed that higher Adenine (A) and 
Thymine (T) content of the surrounding introns correlated with a decrease in exon skipping. 
The DNT mutant showed a larger effect than DE16, and barely any differences were found 
within exons. 
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Figure 40. Nucleotide composition is implicated in alternative splicing. The AT content (%) was analysed for 
exons alternatively spliced in Dido DNT (left) and DE16 (right). Black line shows a random selection of unaltered 
exons that was used as control. Red line represents exons undergoing significantly increased skipping and blue 
line depicts exons that were less skipped (more included) in Dido mutants as compared to WT. 200 bases 
upstream and downstream of the selected exons were taken into account, and exons were scaled to a 100 base 
pair window. Error bars depict SD and were derived from a 5 x 1000 random sampling. 
 
After showing that intron composition influences the splicing of the upstream exon, 
we searched for specific motifs in these regions that could be associated with splicing. 
Different sequences have been linked to splicing regulation. Specifically, short AT-rich motifs 
have been associated with pausing of the transcription elongation complexes (Palangat, 
Hittinger et al. 2004, Saldi, Cortazar et al. 2016). Based on the “window of opportunity” 
model, if the RNAPII encounters a pause site, this could promote the utilization of upstream 
3’SS that are not usually included. We thus searched for all combinations of nucleotide 
pentamers (5-mers) downstream the altered exon. The frequency of each 5-mer was 
calculated for both Dido mutants, while discriminating between exons undergoing more or 
less skipping (Figure 41). These results indicated that AT-rich sequences, located 
immediately downstream (<200 bp) of the spliced exon, were predominant in significantly 
less skipped exons. In addition, the motifs that contained a higher Thymine content were 
associated with the more included exons in both mutants.  
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Figure 41. AT-rich motifs promote exon inclusion in Dido mutants. The scatter plots show the frequency of 
different 5-mer combinations measured in the first 200 bp downstream of significantly altered exons in Dido 
DNT (left) and DE16 (right) mutants. A group of 5-mers with significant changes is marked with their associated 
sequences. The error bars of this group represent standard deviation and were derived from a random selection 
of 5 x 1000 5-mers. The diagonal discontinuous line indicates no alteration in exon usage. 
 
 Although both Dido mutants exhibited similar plots, these T-rich motifs contributed 
more to exon inclusion in DNT than in DE16. Furthermore, although exon bodies did not 
presented significant changes in nucleotide composition (Figure 41), exonic splicing 
regulatory sequences (ESRs) have been associated with alternative splicing regulation 
(Goren, Ram et al. 2006). The ESRs are recognized by different splicing factors such as 
SRSF1, which has been related with specific purine-rich motifs (Tacke and L.Manley 1995, 
Cavaloc, Bourgeois et al. 1999, Schaal and Maniatis 1999). Thus, we also searched for 5-mer 
combinations within alternatively spliced exons (Figure 42). 
SRSF1 sequences were found in exons that were significantly less skipped in Dido 
mutants. Thus, the presence of these sequences as well as the T-rich motifs correlate with 
exon inclusion. While T-rich clusters contributed more in the DNT mutant, putative SRSF1 
motifs had a stronger effect in DE16 samples. 
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Figure 42. SRSF1 recognition motifs are associated with exon inclusion in Dido mutants. Both scatter plots 
show the frequency of 5-mer sequences located in exons that are skipped significantly more (vertical axis) or 
less (horizontal axis) in DNT (left) and DE16 (right) mutants. 5-mers undergoing the biggest changes are marked 
with the associated sequences. SRSF1 recognition motifs are highlighted in bold. The error bars of this group 
represent standard deviation and were derived from a random selection of 5 x 1000 5-mers. The diagonal 
discontinuous line indicates no alteration in exon skipping. 
 
 
3.5. T-rich motifs downstream of exons promote their inclusion 
In order to confirm that the T-rich motifs were related with the inclusion of some 
exons in Dido mutants, we decided to use the HeLa Flp-InTM T-RexTM system and generated 
minigenes with or without such sequences. The model used for minigene generation was the 
Ndufs7 and Dazap1 gene fusion. In our DE16 mutant, fusion transcripts were produced from 
the penultimate exon of Ndufs7 to the second exon of Dazap1 (see Figure 24). We selected 
these genes because the behaviour of the splicing junctions differed between mouse and 
human models even though similar fusion transcripts were found. In the mouse model, the 
aberrant splicing events started at the end of the last exon of Ndufs7, before the 3’UTR, and 
ended at the second exon of Dazap1 (Figure 43A). However, in the human model, aberrant 
splicing began at the end of the Ndufs7 penultimate exon, and finished at the second exon of 
Dazap1 (Figure 43B). Fusion transcripts were generated in both cases, although only the 
Ndufs7 3’UTR was skipped in the mouse model while the whole last exon and 3’UTR were 
excised in the human model. Interestingly, when checking the intergenic region between 
both genes, a long T-rich sequence downstream of the 3’UTR was found only in the mouse 
model (Figure 43C). Since T-rich motifs were related with exon inclusion in our mutants, we 
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tried to reproduce both mouse and human models by changing only the T-rich intergenic 
region with a minigene.  
Thus, a minigene containing the last two exons of Ndufs7, the first and second exons 
of Dazap1, and an intermediate region with the T-rich motif or a random sequence was 
generated (Figure 44A). The complete minigene was cloned into a pcDNATM5-FRT-TO 
vector and stably transfected into HeLa-FLP WT and DE16 cells. Minigene expression was 
induced with 1 µg/ml of doxycycline for 72 hours and the generation of the fusion transcript 
was tested by Reverse transcriptase PCR (Figure 44B). Although formation of a fusion 
transcript was observed in all samples, skipping of the whole Ndufs7 last exon only took place 
in the DE16 mutant and when the T-rich sequence was lacking. The absence of a T-rich motif 
mimicked the human situation in the Dido mutant, while the presence of these sequences 
promoted inclusion of the Ndufs7 last exon. Surprisingly, all minigenes produced fusion 
transcripts even in WT HeLa-FLP cells. This effect might be produced because only two exons 
from each gene were cloned at a reduced intergenic distance, likely simulating the structure 
of one single gene. Minigene construction thus favoured the splicing between Ndufs7 exon 8 
and Dazap1 exon 2 similar to a normal splicing event instead of an intergenic fusion. 
Finally, these results confirm that downstream T-rich regions may help to include 
upstream exons in our Dido mutants. This effect could be related with the previously 
mentioned RNAPII pause sites (Palangat, Hittinger et al. 2004, Saldi, Cortazar et al. 2016). 
The T-rich motif found near the mouse Ndufs7 gene is 800 bp downstream of the included 
exon. However, the T-rich 5-mers identified in both Dido mutants were located only 200 bp 
downstream of the included exon (Figure 42). Thus, other factors might influence the use of 
this T-rich sequence as a pause site in the case of the fusion of Ndufs7 and Dazap1. We 
hypothesize that the strength of the sequence, since it was a very long motif, and the high 
content in thymine nucleotides could promote RNAPII arrest.  
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Figure 43. Ndufs7 and Dazap1 fusion transcripts are generated by different splicing events in mouse and 
human cells. (A) Schematic representation of the Ndufs7 and Dazap1 fusion transcript in mouse cells (MEFs). 
The splicing event begins at the 3’UTR of Ndufs7 and ends at the second exon of Dazap1. (B) Schematic 
representation of the Ndufs7 and Dazap1 fusion transcript, this time in human (HeLa-FLP) cells. Here, the 
splicing starts at the Ndufs7 penultimate exon and again finishes at the second exon of Dazap1. (C) IGV 
visualization of the downstream sequences of Ndufs7 in mouse and human cells. 
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Figure 44. T-rich sequences promote the inclusion of Ndufs7 last exon. (A) Schematic representation of the 
two cassettes generated for the minigenes, with and without the T-rich region. (B) Reverse Transcriptase PCR 
experiments show that only in the absence of T-rich sequences downstream of Ndufs7, the last exon is skipped. 
Representative image of three independent experiments. 
 
 
 Together, the results presented in this thesis project link DIDO3 protein with 
alternative splicing. The DIDO3 interaction with SFPQ and its role in SFPQ recruitment 
to messenger RNA connect our protein to U2 snRNP positioning. In addition, the 
differences found in exon skipping and inclusion seem to depend on 3’SS utilization and 
SFPQ occupancy. Our data thus indicate the existence of a DIDO3-SFPQ axis acting in 
alternative splicing regulation. The presence of additional sequences, such as T-rich 
motifs and SRSF1 recognition sites, affect the splicing pattern in our mutants. This 
implies an alternative regulatory pathway, likely involving RNA polymerase II. 
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1. The evolution of DIDO3/exon 16 satisfies a requirement in alternative splicing 
RNA splicing is a complex process that is highly conserved among organisms (De 
Conti, Baralle et al. 2013). Although it was considered for decades as a post-transcriptional 
process, most recent publications couple splicing and transcription as simultaneous events 
(Neugebauer 2002, Oesterreich, Herzel et al. 2016, Herzel, Ottoz et al. 2017). Alternative 
Splicing is a variation of splicing that is prevalent in vertebrates, and allows the generation 
of multiple isoforms of the same messenger RNA (Chow LT, RE et al. 1977). While the basic 
principles of splicing are conserved in all eukaryotes, alternative splicing requires additional 
levels of regulation (Keren, Lev-Maor et al. 2010). One of the most studied mechanisms 
implicated in this regulation is the correct positioning of the U1 and U2 snRNP on splice donor 
and acceptor sites. Since U1 interacts directly with the mRNA, 5’SS recognition does not 
involve helper proteins (Spiluttini, Gu et al. 2010). However, U2 placement requires 
additional factors. Correct 3’SS recognition by the U2 snRNP is guided by accessory splicing 
factors, such as U2AF, SR family or SFPQ proteins (Ruskin, Zamore et al. 1988, Patton, Porro 
et al. 1993, House and Lynch 2008). Thus, the splice acceptor site is a frequent point of 
interest to study alternative splicing regulation. 
In this thesis project, we studied the role of the DIDO3 protein in alternative splicing. 
We show that DIDO3 acts as a 3’SS modulator through SFPQ recruitment. Although the Dido 
gene encodes for three different isoforms that contain several domains, we focused on 
DIDO3, the longest protein. This large isoform is only produced in vertebrates, whereas 
DIDO1 and DIDO2 can be found in all eukaryotes (Rojas, Sanchez-Pulido et al. 2005). No 
conserved domains have been assigned to the DIDO3-specific region that is encoded by exon 
16. However, the smaller isoforms such as DIDO1 and DIDO2 have been described in more 
detail. The association of these isoforms with histones and the transcription machinery is 
mediated by the PHD and TFS2M domains, respectively (Gatchalian, Futterer et al. 2013, 
Futterer, de Celis et al. 2017). Since DIDO3 expands the modular structure of the smaller 
isoforms, it may simply add another function related to RNA metabolism.  
Different lines of evidence connect the DIDO3-specific domain to alternative splicing. 
Regarding evolution, this type of specialized splicing is extensively used in vertebrates, the 
same organisms where the DIDO3 full-length protein is found. In lower eukaryotes (insects 
and yeast), some alternative splicing occurs but is not the dominant form of splicing. BLAST 
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searches found homologs of SFPQ, one of the major DIDO3 interactors, in chordates and 
arthropods but not in lower eukaryotes. We thus hypothesize that DIDO3 and SFPQ 
appeared at the same time and evolved together. The combination of the two may provide 
an extra level of regulation in the splicing process.  
 
2. DIDO3 and SFPQ, two very different but closely related proteins 
 In this project, we proved that SFPQ interacts specifically with DIDO3, because no 
binding was found with the shorter isoforms (Figure 11). Although this interaction was not 
assigned to any particular protein domain, the coiled-coil in both DIDO3/exon 16 and SFPQ 
is a good candidate. A close look into the modular structure of SFPQ finds similarities with 
the DIDO3 carboxy-terminus. SFPQ belongs to the DBHS or Drosophila behaviour/human 
splicing protein family, together with NONO and PSPC1. This family is implicated in several 
steps of gene regulation including RNA transcription, splicing, and even RNA transport. The 
three proteins contain tandem RRMs, a coiled-coil, and a NOPS protein-protein interaction 
domain (Knott, Bond et al. 2016). SFPQ homodimers interact via their coiled-coil 
oligomerization motifs. The same domain is also involved in the heterodimerization and 
oligomerization of the DBHS protein family, facilitating their interaction (Lee, Sadowska et 
al. 2015). Thus, although the DIDO3 carboxy-terminus is very unstructured and disordered, 
it contains short regions similar to SFPQ, such as the coiled-coil and an RRM domain. 
Disordered regions are common in RBPs and splicing factors of recent evolution (Haynes and 
Iakoucheva 2006, Jarvelin, Noerenberg et al. 2016). In addition, DIDO was found in several 
proteomics screenings for RNA-interacting proteins, although these analyses did not 
discriminate what isoform was detected (Baltz, Munschauer et al. 2012, Castello, Fischer et 
al. 2012). Indeed, our iCLIP experiments suggested that DIDO3 is a bona fide RBP (Figure 
18D), potentially implicating the RRM domain. These results fit with the idea of a DIDO3 
protein that is involved in alternative splicing and uses the protein domain encoded by exon 
16 as a link to SFPQ and mRNA. This idea is also supported by Isoginkgetin and PLA 
experiments, where the lack of this exon 16 reduced the recruitment of SFPQ to spliceosomal 
complexes (Figure 13A and 17). The observation that hnRNP U, another DIDO3 interactor, 
did not colocalize with DIDO when splicing was inhibited denotes SFPQ specificity (Figure 
13C).  
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 Several studies have proposed that SFPQ is recruited to the nascent transcript by the 
RNAPII CTD (Emili, Shales et al. 2002, Rosonina, Ip et al. 2005). However, a later study could 
not confirm a relationship of SFPQ with the polymerase (Das, Yu et al. 2007); this study 
proposed that only other splicing factors such as SRSF1 associate with RNAPII CTD. These 
authors claimed that the SRSF1 protein, together with the U1 snRNP, are recruited via the 
CTD and positioned close to the mRNA. The CTD seems to compete with an independent 
pathway that is governed by hnRNP negative factors, to regulate spliceosome assembly 
(Das, Yu et al. 2007). Whether or not SFPQ is recruited via the CTD, we showed that DIDO3 
is one of the sources of SFPQ delivery to RNA transcripts. PAR-CLIP experiments revealed 
that SFPQ accumulation and binding to mRNA are significantly reduced in our Dido mutants, 
particularly in the one lacking the SFPQ-interacting region (DE16) (Figure 34). We thus 
envision that DIDO3 forms a bridge between RNAPII and SFPQ, connecting through the 
TFS2M domain (Kinkelin, Wozniak et al. 2013, Futterer, de Celis et al. 2017) and carboxy-
terminal region, with the objective to place the latter protein close to the nascent RNA 
(Figure 45).  
 
Figure 45. Schematic model of the DIDO3 full-length protein (brown) associated with RNAPII and SFPQ. 
Here, the coiled-coil domain would recruit SFPQ to help the correct positioning of U2 on the 3’SS of nascent 
RNA. In a parallel pathway, other SF such as SRSF1 assist U2 snRNP and regulate exons independently. The 
PHD domain binds DIDO3 to the chromatin and the TFS2M and SPOC domains manage RNAPII association. 
The putative RRM could also be implicated in direct binding of DIDO3 to the RNA.  
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This model is further supported by PLA experiments that measured the interaction 
between SFPQ and the RNAPII (Figure 46). While SFPQ recruitment to the RNAPII seems to 
be unaffected in the DE16 mutants, the lack of the PHD domain in DNT reduces SFPQ 
interaction with the polymerase. The latter mutant might somehow interfere with an 
RNAPII-dependent route of SFPQ recruitment. 
 
Figure 46. SFPQ recruitment to RNAPII is reduced in DNT mutants. Immunofluorescence images of 
Proximity Ligation Assays between SFPQ and RNAPII (left) in WT and Dido mutants. Red spots represent 
proximity between both proteins, while nuclei are depicted in blue. The control sample was labelled with only 
one antibody. The antibody used for RNAPII detection recognizes the CTD repeat YSPTSPS. PLA signal 
quantitation (right) revealed a significantly reduced fraction of SFPQ close to RNAPII in DNT mutants compared 
to WT and DE16 mutant cells. Error bars represent standard deviation. ***p<0.001. 
 
3. Dido mutations correlate with SFPQ-associated splicing defects 
 Since splicing factors are necessary for correct cell development, generation of 
relevant mutants has always been a difficult process. Indeed, mutations associated with 
different splicing factors are directly involved in several pathologies and especially in cancer 
(Oltean and Bates 2014, Singh and Eyras 2017). When factors such as SF3B1, U2AF1 or SRSF2 
are mutated, they promote the development of haematological malignancies (Cheng, Luo 
et al. 2016, Dvinge, Kim et al. 2016). While the constitutive knock-out of NONO and PSPC1 
was possible (Li, Li et al. 2014) different attempts to generate SFPQ insufficiency by 
immunodepletion have been unsuccessful (Patton, Porro et al. 1993, Gozani, Patton et al. 
1994). Furthermore, recent studies published the generation of SFPQ null mutants in 
zebrafish and mouse, but SFPQ silencing in both models was incompatible with long term 
cell viability (Thomas-Jinu, Gordon et al. 2017, Takeuchi, Iida et al. 2018). Nevertheless, we 
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were able to delete large portions of Dido (DNT and DE16) while maintaining cell viability 
(Figure 14 and 15). Our mutants allowed the study of splicing defects without disrupting any 
canonical factor that affected cell survival. Nonetheless, several thousand of splicing 
alterations were found in both mutants, most of them regarding exon skipping and exon 
inclusion (Figure 20). Since the presence of these alternative splicing events were confirmed 
in a human model (Figure 28, 29, 30 and 31) we assumed a direct relation with the Dido 
mutations.  
  After having determined that DIDO3 acts by recruiting SFPQ, some kind of 
correspondence between the lack of SFPQ and DIDO3 was expected. Given the impact of 
SFPQ deletion, reduced cell viability might compromise RNA sequencing data in these 
models (Takeuchi, Iida et al. 2018). The same studies however included WT controls that 
could be analysed. Indeed, evaluation of the SFPQ dependency of the exons with altered 
splicing in our Dido mutants showed a positive correlation (Figure 36). Exons skipped 
significantly more in our mutants correlated with a high SFPQ occupancy, while exons 
included more presented lower SFPQ association levels. This correlation with SFPQ 
occupancy fits with the general idea of splicing factor recycling. As mentioned in the 
introduction, spliceosome formation is a very dynamic process. Many splicing factors need 
to be re-used for every cycle of splicing, sometimes even in exons from the same gene 
(Medenbach, Schreiner et al. 2004, Wahl and Lührmann 2015). This recycling process is quite 
important, because the maintenance of a reservoir of free subunits may decide the inclusion 
or skipping of certain exons. In line with this hypothesis, suppression of recycling strongly 
reduces RNA splicing yield, and mostly affects exons containing weak U2-binding sites. A 
general lack of splicing factor availability impairs proper splice site recognition by the 
spliceosome. The resulting splicing suppression may even lead to different pathologies and 
cancer (Han, Park et al. 2017). At least one publication reports that loss of SFPQ mainly 
affects long genes (Takeuchi, Iida et al. 2018). The sequencing data in this publication show 
a reduction but not complete absence of SFPQ. Possibly, long genes suffer more because 
their transcription requirements (a prolonged burst of transcription) easily deplete the 
remaining SFPQ pool. Although our data show no changes in total SFPQ levels, Dido 
mutations affect recognition of U2-binding sites as evidenced by excessive exon skipping. 
Thus, instead of global availability, SFPQ recruitment to individual RNA transcripts is 
diminished.  
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The group of skipped exons are typical SFPQ targets and can be easily explained by 
the 3’SS utilization parameter. Exons that already in WT cells showed more skipping than 
unaltered exons were affected more in the Dido mutants (Figure 37). Thus, a decrease in 
SFPQ availability impairs the proper recognition of 3’SS and promotes the skipping of the 
corresponding exon. However, the analysed data also showed a second group of 3’SS that 
were used more frequently in our mutants (Figure 38). To explain this second group, we 
again refer to the model where SFPQ is recruited from a shared pool. Thus, when access of 
SFPQ to one 3’SS subset is reduced in the mutants, its availability for the remaining 3’SS 
automatically increases. The data agree with this model, because a second group of exons 
benefit from the increased SFPQ availability and are included more in the mutants than in 
the WT. SFPQ occupancy in this group was lower than in skipped exons, suggesting low 
SFPQ dependency or faster processing.  
 
4. Downstream motifs are implicated in exon skipping and inclusion 
Different publications have described the importance of downstream sequences on 
splice site selection (Goren, Ram et al. 2006). Thus, parameters different from splice site 
strength or utilization may explain whether an exon is included or skipped. Exons 
significantly more included in both Dido mutants showed downstream repetitive sequences 
rich in Adenine (A) and Thymine (T) (Figure 40). These AT-rich motifs have been associated 
with RNA polymerase II pause sites in various studies (Artsimovitch and Landick 2000, 
Palangat, Hittinger et al. 2004, Nudler 2012). This delay in RNA processing, which sometimes 
can persist for minutes (Henriques, Gilchrist et al. 2013), affects splice site choice because it 
extends the so-called window of opportunity (Aebi and Weissmann 1987, Kornblihtt, Schor 
et al. 2013, Saldi, Cortazar et al. 2016). The general hypothesis indicates that these pause 
sequences reduce RNAPII speed, thereby facilitating the inclusion of exons with weak or less 
used 3’SS (Roberts, Gooding et al. 1998, Carrillo Oesterreich, Preibisch et al. 2010).  
In our Dido mutants, two separate factors are promoting the increased inclusion of 
some exons: SFPQ availability and AT-rich motifs. As we discussed in the previous section, a 
reduced SFPQ availability favours the selection of exons that are less SFPQ-dependent. At 
the same time, AT-rich motifs would pause the RNAPII, thereby promoting inclusion of 
upstream exons. Together, both situations interfere with the normal splice site selection and 
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promote the inclusion of a subset of exons included less frequently in the WT. This effect was 
also found in other organisms with Dido homologs, such as D.melanogaster. The PPS protein 
is a DIDO homolog that favours skipping of the Sxl exon that determines male sex. However, 
in the absence of PPS, inclusion of this exon could be explained by an RNAPII pause in the 
AT-rich stretches found downstream the exon. 
We generated minigenes containing these pausing sequences in order to confirm the 
effect in exon inclusion (Figure 44A). The Ndufs7 and Dazap1 genes showed different fusion 
transcripts in human and mouse DE16 mutants. Since the most striking difference was the 
presence of a long T-rich motif downstream the 3’UTR of Ndufs7 (Figure 43), they were good 
candidates for minigene design. As expected, the presence of the alleged pause site always 
promoted the inclusion of the Ndufs7 last exon and thereby confirmed the effect of the T-
rich sequence (Figure 44B).  
In addition, a 5’ cryptic splice site is located at the end of the Ndufs7 last exon, exactly 
at the place where the splicing event of the fusion transcript starts (Figure 47). Both human 
and mouse genes contain this U1 snRNP recognition site, but only the mouse model includes 
the exon. We hypothesize that the pause imposed by the T-rich region creates a window of 
opportunity for U1 to recognise the cryptic 5’SS. Due to a mechanism termed telescripting 
(Kaida, Berg et al. 2010, Berg, Singh et al. 2012), U1 binding favours the U2 positioning at the 
upstream 3’SS and inhibits PAS recognition by the polyadenylation machinery. The 
combination of the two actions promotes exon definition of the Ndufs7 terminal exon and 
subsequent splicing to the next available 3’ acceptor site. This latter splice site is the one 
located in the second exon of Dazap1. Although the cryptic 5’SS is encoded by the human 
genome, absence of the pause site precludes its recognition. 
Additionally, our Dido mutants show a relationship with splicing factors other than 
SFPQ. In the mutants, many exons that were included significantly more contained SRSF1 
recognition sites (Figure 40). Since the SRSF1-RNAPII pathway has been previously 
described (Tian and Kole 2001, Pandit, Zhou et al. 2013), we hypothesize that exons using 
this alternative pathway could benefit from the changes in SFPQ availability in the DE16 
mutant. In the end, different pathways that control 3’SS usage converge on the U2 snRNP. 
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The observation of SRSF1 recognition motifs in our sequencing data thus indicates that this 
pathway competes with SFPQ for U2 snRNP positioning.  
	
Figure 47. A cryptic 5’SS is located at the end of the Ndufs7 last exon. Schematic representation of mouse 
Ndusf7 and Dazap1 genes depicts the 5’ cryptic splice site and the T-rich region. In the box below, the region of 
the Ndufs7 last exon and 3’UTR was magnified. The light blue lines and the red arrow depict the cryptic 5’SS. 
 
5. Lack of histone binding reduces the DIDO3 reservoir at the TSS 
 Although the lack of exon 16 reduces SFPQ accessibility for the splicing process, the 
DNT mutant still contains this region. We assumed that the ability to recruit SFPQ is intact in 
this mutant, according to the mild defects observed in splicing and related PAR-CLIP 
experiments. In the DNT mutant, exons 3 and 4 were eliminated, affecting the binding to the 
H3K4Me3 (Futterer, Campanero et al. 2005, Gatchalian, Futterer et al. 2013). Thus, the 
connexion with splicing could be conserved but the association with the chromatin is 
disrupted. Cases similar to the DNT mutant have been reported in the literature. For example 
CHD1, a modular protein with domains that perform a function comparable to DIDO3. This 
protein, too, is implicated in transcript elongation and termination in yeast, drosophila and 
mammals (Sims, Belotserkovskaya et al. 2004). CHD1 associates with the U2 snRNP 
component SF3A and contains a chromodomain that promotes H3K4Me3 binding. Like 
DIDO3, this protein accumulates at the Transcription Start Site (TSS) via histone binding and 
recruits U2 snRNP to the spliceosome, enhancing the efficiency of splicing and transcription 
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elongation (Sims, Millhouse et al. 2007). In the case of the DNT mutant, the lack of a PHD 
domain impairs histone binding and may prevent accumulation of DIDO3 at the TSS of the 
genes. Indeed, the reduction of DIDO3 availability affects downstream SFPQ recruitment 
and the amount of this protein that binds to the mRNA (Figure 34).  
Since the H3K4Me3 mark is associated with active transcription (Ruthenburg, Allis et 
al. 2007), the associated chromatin is subjected to continuous passes by RNAPII. During 
mitotic division, the chromatin is highly condensed and transcription is suppressed (A. and I. 
2005). When mitosis is completed, chromatin returns to a more relaxed state and 
transcriptional programs, including splicing, are rapidly re-initiated. Because H3K4Me3 is 
closely associated with RNAPII transcription, proteins that recognize this mark are also 
expelled from the chromatin in mitosis (Gatchalian, Mora Gallardo et al. 2016). Apparently, 
the bulk of proteins bound to the TSS can interfere with chromatin condensation. Thus, 
phosphorylation of serine and threonine residues next to prominent methylations ensure the 
exclusion of histone readers and liberate the chromatin for condensation (van Wely, Mora 
Gallardo et al. 2017). At the end of mitosis, this situation is reverted. Transcription resumes 
as soon as possible in the daughter cells, in order to preserve cell identity. To restore gene 
expression after mitosis, the H3K4Me3 mark, through histone-readers, acts as an active 
recruiter of transcriptional complexes. While the H3K4Me3 mark is maintained in the 
chromatin during mitosis, reader proteins are completely excluded. The exclusion of histone 
readers could expose the H3K4Me3 mark to demethylases, and thus change gene expression 
patterns. The rapid and massive phosphorylation on adjacent residues at the onset of mitosis 
thus prevents binding of transcription-related proteins and demethylases alike. As soon as 
chromatin relaxes and other histone marks such as phosphorylation are removed, histone 
readers rapidly bind to H3K4Me3. This accumulation at the TSS of active genes initiates the 
correct gene expression programs (Gatchalian, Mora Gallardo et al. 2016). Some of these 
histone-readers are proteins with PHD domains, such as ING1, TAF3, DIDO3 or PHF8. The 
implication of DIDO3 as an histone reader, places our protein already close to the DNA. Given 
the interplay between H3K4Me3 and transcription, recognition of this mark by DIDO already 
implicates the protein in this process. Importantly, the H3K4Me3 mark is compressed close 
to the TSS in non-spliced genes but extends far into the first intron in spliced genes 
(Bieberstein, Carrillo Oesterreich et al. 2012). We thus assume that a rapid placement of 
DIDO3 at the 5’ end of genes could help in the generation of a DIDO3 reservoir for subsequent 
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RNAPII passes. This situation is impaired in the DNT mutant since the interaction with the 
H3K4Me3 is disrupted, resulting in the observed splicing defects. 
 
6. Splicing alterations might provoke the phenotypes associated with Dido mutations  
Several phenotypes have been associated with the lack of distinct DIDO regions. 
Since the deletion of the full-length protein is incompatible with life, different mutants were 
generated over the years. Absence of the N-terminal part, including the PHD domain, 
produced mitotic spindle defects (Trachana, van Wely et al. 2007), cell division problems and 
chromosome instability (Guerrero, Gamero et al. 2010, Martinez and van Wely 2011). In 
addition, haematological myeloid neoplasms have been reported in mice carrying the DNT 
mutation (Futterer, Campanero et al. 2005). On the other hand, constitutive absence of exon 
16 is lethal at embryonic stage 8.5 of gestation (Futterer, Raya et al. 2012). In this case, the 
lack of exon 16 affected embryonic stem cell (ESC) differentiation (Futterer, de Celis et al. 
2017) and impaired iPSC reprogramming (unpublished work). Because of the severity of 
constitutive deletion, conditional exon 16 knock-outs were generated (Figure 15). In Dido 
mutants that survive, a wide variety of alterations is observed. Different types of ciliopathies 
for example, brain malformations and neuromuscular and behavioural alterations have been 
associated with a DNT/DE16 mutant (Villares, Gutierrez et al. 2015). More recently, lack of 
exon 16 in the hematopoietic lineage was shown to compromise HSCs differentiation, 
affecting the B cell lineage (unpublished work). 
Since DIDO3 is a modular protein, the diversity of these phenotypes could be 
explained due to the wide range of interactions found for DIDO. However, alterations in 
splicing may be another explanation for the different processes that seem to be regulated or 
affected by Dido mutations. Although the final phenotypes affect apparently unrelated cell 
types, the large number of genes that show altered splicing could partially overlap with 
multiple cell-specific expression patterns. In addition, the generation of aberrant mRNA 
transcripts as a consequence of splicing alterations may lead to the activation of interferon-
related genes. Usually, these responses are similar to a viral infection (Zevini, Olagnier et al. 
2017). Indeed, gene ontology analyses showed several pathways upregulated in our mutants, 
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including responses to interferon and defensive strategies against virus or viral production 
(Figure 26).  
Mis-regulation of genes that are affected in our mutants may lead to different 
outcomes. It is important to notice that the splicing alterations that we found, were not 
“black or white”. In most of the cases, a normal transcript was also produced, and only a 
percentage of the splicing products resulted in aberrant messenger RNAs. However, in some 
cases, this small percentage of altered transcripts could be sufficient to affect gene function. 
Here, the case of Ndufs7 and Dazap1 was a clear example of such changes in functionality. In 
DE16 mutants, a fusion transcript between both genes was generated. The splicing event 
between consecutive genes skipped the last exon of Nudfs7 and the first exon of Dazap1 in 
human cells (Figure 29). Since the fusion transcript was in frame, a fusion protein was also 
produced (Figure 30A). Interestingly, NDUFS7 is a cytoplasmic protein whereas DAZAP1 
remains inside the nucleus. Due to the fusion protein, human DE16 cells showed a higher 
concentration of NDUFS7 in the nucleus compared to WT cells (Figure 30B). Here, this 
aberrant splicing event was affecting the protein localization and possibly its function. 
Indeed, in the case of DAZAP1, the two RRM domains located at the N-terminal region are 
disrupted. Since DAZAP1 is an RBP implicated in mammalian development and 
spermatogenesis, the lack of RNA interaction could affect its function on splicing itself.  
Together, our data indicate a role for DIDO3 in the regulation of alternative splicing. 
A DIDO3-SFPQ axis controls the 3’SS selection in a subset of exons that are highly SFPQ-
dependent. In parallel, the RNAPII-SRSF1 axis could promote the inclusion of another group 
of exons by the help of exon recognition motifs. Both axes could benefit from downstream 
pause sites. Since DIDO3 binds to SFPQ and RNAPII at the same time, both pathways 
cooperate to promote effective 3’SS utilization and increase the efficiency of the splicing 
process. In addition, DIDO3 accumulates at the start site of active genes through the PHD 
domain, generating a reservoir to be used after transcription initiation. Since splicing is 
mostly produced co-transcriptionally, DIDO3 travels along the DNA bound to RNAPII, in the 
meantime recruiting SFPQ to the mRNA. When exon 16 is eliminated, the connexion with 
SFPQ disappears and therefore the regulation by the DIDO3-SFPQ axis. Thus, exon skipping 
is increased due to altered 3’SS utilization (Figure 48). On the other hand, when the PHD 
domain is removed, the DIDO3 reservoir is absent, reducing the amount of DIDO3 ready to 
DISCUSSION 	
	 126	
recruit SFPQ. This situation also promotes exon skipping of SFPQ-dependent exons but can 
be overcome by RNAPII pausing (Figure 49).  
 
Figure 48. Schematic model of the D16 mutant in RNA metabolism. The lack of interaction with SFPQ 
impairs correct delivery of this splicing factor to the 3’SS of a subset of exons. Although U2 snRNP is still 
recognizing the 3’SS, alternative helper proteins such as SRSF1 may contribute. 
 
Figure 49. Schematic model of the DNT mutant in RNA metabolism. The absence of the PHD domain 
eliminates the connexion with histones and consequently with the DNA. DIDO3 cannot be accumulated at the 
TSS of the genes and less SFPQ is delivered to the nascent RNA. Consequently, pathways that support posterior 
recruitment such as RNAPII pause sites could be implicated in the correct splicing of exons. 
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An important consequence of these models is the inferred competition between 
DIDO2 and DIDO3. Since these isoforms share the TFS2M domain but not the SFPQ 
interaction, binding of DIDO2 to RNAPII could limit the possibility to recruit SFPQ. RNA 
sequencing of heterozygous WT/DE16 MEFs indeed revealed an intermediate level of exon 
skipping (unpublished data). The exact mechanisms that regulate the production of DIDO 
isoforms in mammals remain to be described. The termination of each isoform in a bleeding 
exon however implicates telescripting in DIDO isoform selection. A surprising albeit 
unproven consequence is that DIDO isoforms could functionally link U1 and U2 snRNPs 
through this mechanism. 
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1. The Dido exon 16 that corresponds to the DIDO3 isoform is necessary for SFPQ 
interaction. The importance of a coiled-coil domain for SFPQ function and presence of a 
similar domain in DIDO3/exon 16 indicates that the interaction could be mediated by this 
region. 
2. DIDO3 recruits SFPQ to the messenger RNA and Dido mutations alter subnuclear SFPQ 
distribution when splicing is impaired. Given the effect of the Isoginkgetin inhibitor on 
splicing, DIDO3 and SFPQ seem to act upstream of spliceosome assembly.  
3. Elimination of the Dido exon 16 (DE16) causes thousands of alternative splicing defects, 
which have been verified in mouse and human models. Most of these events involve 
alterations in exon skipping. As the absence of the exon 16 reduces SFPQ recruitment, 
this might impair positioning of the U2 snRNP on the 3’SS. 
4. Deletion of the exons 3 and 4 of Dido (DNT) also produces thousands of alternative 
splicing defects in a mouse model. However, the number of alterations in exon skipping 
is lower and the amount of exon inclusion events increases compared to the DE16 
mutant. Since the exon 16 is still intact, the availability of SFPQ is higher than in the DE16 
mutant. However, absence of the PHD domain might reduce DIDO3 accumulation at the 
start site of the genes. Reduced DIDO3 presence on active genes, too, affects SFPQ 
recruitment, but its impact is lower as compared to exon 16 deletion. 
5. Interferon-related pathways are upregulated in both Dido mutants. The activation of 
interferon-related genes and viral defense responses is thus associated with the 
production of aberrant RNA transcripts. 
6. Splicing alterations in human Dido mutants are partially corrected by complementation 
with the full-length DIDO3 protein, to a situation that resembles the WT phenotype. 
Since DIDO2 overexpression produces alterations similar to DIDO3 absence, the shared 
PHD and RNAPII-linked domains could produce competition between both isoforms. 
7. SFPQ-dependent exons are affected most by the lack of the DIDO3-SFPQ interaction. In 
these exons, the downstream 3’SS are more utilized than the upstream sites. This 
change in splice site utilization promotes an increase in exon skipping. 
8. Downstream sequences promote exon inclusion under conditions of impaired SFPQ 
recruitment. T-rich regions, which are associated with RNAPII pause sites, preferentially 
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facilitate the inclusion of exons that are less SFPQ-dependent in the DNT mutant. Exonic 
SRSF1 recognition motifs promote the inclusion of exons in the DE16 mutant, by 
facilitating their 3’SS utilization. 
9. A likely scenario for DIDO3 indicates that histone binding accounts for accumulation of 
the protein at the start site of genes. During transcription, dynamic association with 
RNAPII positions DIDO3 near the nascent RNA, thereby promoting SFPQ delivery to the 
messenger RNA and favouring proper recognition of the 3’SS. 
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1. El exón 16 de Dido, que corresponde a la isoforma DIDO3, es necesario para la 
interacción con SFPQ. La importancia de un dominio coiled-coil para la función de SFPQ 
y la presencia de otro dominio similar en el exón 16 de la proteína DIDO3 indica que la 
interacción entre ambas proteínas podría estar mediada por esta región. 
2. DIDO3 recluta a la proteína SFPQ al ARN mensajero y las mutaciones de Dido modifican 
la distribución subnuclear de SFPQ cuando el proceso de splicing está comprometido. 
Teniendo en cuenta el efecto del inhibidor Isoginkgetin en el splicing, DIDO3 y SFPQ 
parecen actuar en un paso previo al ensamblamiento del spliceosoma . 
3. La eliminación del exón 16 de Dido (DE16) genera miles de defectos a nivel de splicing 
alternativo, que han sido validados tanto en un modelo de ratón como humano. La 
mayoría de estos eventos suponen alteraciones en el skipping de exones. Dado que la 
ausencia del exón 16 reduce la disponibilidad de SFPQ, esto podría comprometer el 
correcto posicionamiento del U2 snRNP a los sitios 3’ de aceptación. 
4. La deleción de los exones 3 y 4 de Dido (DNT) también genera miles de defectos a nivel 
de splicing alternativo en un modelo de ratón. Sin embargo, comparado con el mutante 
DE16, se han observado un menor número de alteraciones relacionadas con el skipping 
de exones mientras que la inclusión aumentaba. Dado que en este mutante el exón 16 
permanece en la proteína, la disponibilidad de SFPQ es mayor que en mutante DE16. 
Aún así, la carencia del dominio PHD podría reducir la acumulación de DIDO3 en el sitio 
de inicio de los genes, lo que afectaría a su vez al reclutamiento de SFPQ, pero en menor 
medida que en el mutante carente del exón 16. 
5. En los mutantes de Dido, las vías relacionadas con la respuesta a interferón se 
encuentran sobre activadas. La activación de genes de esta vía y de respuesta a la 
defensa viral está asociada a la producción de transcritos de ARN aberrantes. 
6. Las alteraciones de splicing en los mutantes humanos de Dido son parcialmente 
corregidas por la complementación con la proteína completa de DIDO3, observándose 
una situación más parecida al fenotipo silvestre. Dado que la sobreexpresión de la 
isoforma DIDO2 produce alteraciones similares a la ausencia de DIDO3, los dominios 
compartidos PHD y TFS2M podrían estar generando una situación de competición entre 
ambas isoformas.  
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7. Los exones dependientes de SFPQ son los más afectados por la ausencia de interacción 
entre DIDO3 y SFPQ. En estos exones, los sitios 3’ de splicing localizados downstream se 
usan más que los sitios upstream. Este cambio en el uso de los sitios 3’ está asociado a un 
aumento en el skipping de exones. 
8. Las secuencias downstream promueven la inclusión de exones en condiciones en las que 
el reclutamiento de SFPQ está afectado. Regiones ricas en Timina, asociadas a sitios de 
pausa de la ARN Polimerasa II, facilitan la inclusión de los exones que son menos 
dependientes de SFPQ, especialmente en el mutante DNT. Motivos de reconocimiento 
de SRSF1 localizados en exones promueven la inclusión de exones en el mutante DE16, 
facilitando el uso de sus sitios 3’ de splicing.  
9. El escenario más probable para la proteína DIDO3 indica que la unión con la histona 
produce la acumulación de la proteína en los sitios de inicio de los genes. Durante la 
transcripción, la asociación dinámica con la ARN Polimerasa II posiciona a DIDO3 cerca 
de la cadena naciente de ARN, promoviendo el reclutamiento y entrega de SFPQ al ARN 
mensajero y favoreciendo el correcto reconocimiento de los sitios 3’ de splicing.
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